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ABSTRACT 
Psychological stress is common in everyday life, and has been well recognized as one of the 
major contributors to many mental and physical illnesses, such as mental disorders and 
cardiovascular diseases. The association between psychological stress and carcinogenesis 
remains largely inconclusive to date, although possible biological mechanisms, i.e., through 
dysregulation of immune functions and the neuroendocrine axis, have been proposed. The 
overall aim of this thesis is to investigate the impact of psychological stress on cancer 
initiation and progression, using cervical cancer as an example, as well as to investigate the 
mechanistic contributions of immune and neuroendocrine systems to this link in cervical and 
prostate cancers, respectively. 
In Paper I, we assessed whether loss of a family member due to death, as an extremely 
stressful life event, increased the risk of cervical cancer. Based on the Swedish National 
Cervical Screening Register during 1969 to 2011, we conducted two nested case-control 
studies and found that loss was consistently associated with increased risks of abnormal 
cytology, in situ and invasive cervical cancer. Loss was also positively associated with 
HPV16 infection, particularly high viral load and recurrent infections, as well as high-risk 
HPV infections, among 1,696 women who had no cervical cancer. 
In Paper II, we estimated the impact of psychological stress, using stress-related mental 
disorders and stressful life events as proxies, on cervical cancer progression (i.e. cancer-
specific survival) in a national cohort of cervical cancer patients diagnosed during 2002-2011 
in Sweden. Patients exposed to a stress-related mental disorder or stressful life event had a 
31% increased risk of cancer-specific mortality. The association remained statistically 
significant (25% risk elevation) after adjustment for multiple clinical characteristics.  
In Paper III, we examined the signaling of stress-related pathways in tumor tissues of US men 
with lethal prostate cancer, compared with that of men with nonlethal cancer. Using extreme 
case-control design, we identified 113 lethal cases and sampled 291 nonlethal cases from the 
Physicians’ Health Study and the Health Professionals Follow-up Study. We found that 
differential expression of genes within the adrenergic, glucocorticoid, and serotoninergic 
pathways was significantly associated with the risk of lethal prostate cancer.  
In Paper IV, we further evaluated the differential signaling of stress-related pathways 
between lethal and nonlethal prostate cancers sampled from the Swedish Watchful Waiting 
Cohort (all with localized disease). The signaling of serotoninergic pathway was significantly 
associated with the risk of lethal prostate cancer; similar but weaker associations were noted 
for adrenergic and glucocorticoid pathways. We also explored whether germline genetic 
variants could explain such differential signaling. We found the variants of rs2296972 
(HTR2A) and rs33388 (NR3CI) tended to be associated with lethal prostate cancer, as well as 
the expression of specific genes of the serotoninergic and glucocorticoid pathways in tumor 
tissue. 
In conclusion, psychological stress is associated with increased risks of cervical cancer 
initiation, possibly through enhanced oncogenic infection, as well as cervical cancer 
progression. Differential signaling of stress-related neuroendocrine pathways, including the 
adrenergic, glucocorticoid, and serotoninergic pathways, in tumor tissue may contribute to 
prostate cancer progression in both early and relatively advanced prostate cancers; such 
differential signaling in early cancers may, in part, be explained by genetic predisposition.  
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1 INTRODUCTION 
Psychological stress is common in everyday life, and occurs when we are emotionally 
challenged by perceived threats. Stress has been well recognized as one of the major 
contributors to many mental and physical illnesses, such as mental disorders, cardiovascular 
diseases, metabolic disorders, infection, and also increased mortality.(1) The link between 
stress and carcinogenesis, however, remains largely inconclusive to date.(2,3) The current 
evidence lends more support to the role of stress in cancer progression rather than cancer 
initiation, and highlights its varying effects across cancer sites.(2,3) Over the last decade, 
groundbreaking experimental studies have provided insights into the multiple biological 
mechanisms underlying this link.(4,5) For example, stress-induced immune dysfunction may 
predispose individuals to oncogenic infections, proposing a potential particular link to 
infection-related cancers including cervical cancer (5) and adrenergic signaling affected by 
stress has been demonstrated to play a pivotal role in several cancers, including prostate, 
breast and ovarian cancers.(4) 
Human papillomavirus (HPV) infection is a necessary cause for cervical cancer.(6) Most 
women who contract HPV, however, never develop cervical cancer.(7) It is plausible that 
psychological stress may predispose women to oncogenic HPV infections and possible 
subsequent cervical cancer initiation. 
Although the findings linking psychological stress to cancer progression are more consistent 
compared to findings on cancer initiation,(3) very few studies so far have specifically 
examined the impact of psychological stress on cervical cancer survival(8-10), and none of 
these studies have had the statistical power to draw a firm conclusion, likely due to the rarity 
of the disease in developed countries.   
Evidence from cell lines and animal studies underscore the roles of several stress-related 
signaling pathways in the progression of a variety of cancers, including prostate cancer.(4) 
However, data in human settings are lacking and the four major stress-related pathways have 
never been examined simultaneously to understand the different weights of their mechanistic 
contributions to prostate cancer progression. 
Emerging findings further imply that stress-related pathways, particularly adrenergic 
pathway, may exert most pronounced impact on the early stage of cancer progression, in 
order to initiate dissemination(11), but no human studies have evaluated the role of stress-
related pathways specifically in the progression of early-stage prostate cancer. It is also 
largely unknown whether genetic variation contribute to the mechanisms linking stress-
related pathways to prostate cancer progression. 
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2 BACKGROUND 
2.1 PSYCHOLOGICAL STRESS 
In 1915, Walter Cannon first proposed the “fight-or-flight” theory describing how animals 
react to threats.(12) In 1936, Hans Selye first introduced the “general adaptation 
syndrome”,(13) later renamed to the term “stress”, as the non-specific response to any 
noxious stimulus threatening homeostasis - the maintenance of internal stability against 
challenges from the external environment.(14) There are two aspects of stress - the perceived 
stimulus that threatens homeostasis is referred to “stressor”, while the “stress response” is 
defined as the reaction aimed to regain homeostasis.(1) Also, stress is generally classified in 
two different phases – acute and chronic stress – with different influence on our body.(15) 
Given the misuse of the broad definition, Koolhaas and colleagues proposed that the “stress” 
terminology may be applied to uncontrollable and/or unpredictable stimuli only.(16) Of note, 
stress comprises psychological and physical stress; the latter is however out of the scope in 
this thesis.  
Biological Responses 
The hypothalamic pituitary adrenocortical (HPA) axis and sympathetic nervous system 
(SNS) are generally considered as two key players in stress responses. These two master 
systems coordinate and synchronize the peripheral physiology at multiple levels of cells, 
tissues and organs, in interaction with the external environment. When the perception of a 
stressor is processed by the central nervous system, stress hormones are released by the HPA 
axis and SNS as a part of the biological stress response, leading to fast energy mobilization 
and redistribution. The HPA axis releases the hormone cortisol from the adrenal glands into 
the circulation. The SNS secretes catecholamine by nerves and adrenal medulla. 
Consequently, the blood pressure and heart rate increase to deliver more energy, and the 
immune system is activated. The homeostasis will then be re-established if the stressor falls 
within the adaptive capacity. However, the recovery of the physiological action would be 
compromised if the demands continue to exceed the adaptive capacity (i.e., maladaptiveness). 
Due to the fundamental impact of stress hormones on our physiological system, a variety of 
health consequences may accompany the stress response, including changes in neurobiology, 
immune, circulation, metabolism, even mood and behavior, if the reaction is sustained. For 
instance, stress may result in sustained higher blood pressure and vascular hypertrophy 
through chronic SNS stimulation,(17) and altered cytokine profiles and immunity through 
elevated baseline stress hormones.(18) 
Measurement 
The most common approach for stress measurement is through different rating scales. In 
1967, Thomas Holmes and Richard Rahe developed the Social Readjustment Rating Scale 
(SRRS), which assesses the experience of 43 stressful life events during the past six months 
and use the sum of event-specific scores to predict subsequent risk of illness.(19) Later, the 
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SRRS was improved to the Life Experience Survey based on 57 life events. It allows the 
separate assessment on both positive and negative events as well as individualized rating for 
the impact of each event to better reflect the magnitude of perception and coping to individual 
event.(20) Both of these original rating scales have rarely been used in large-scale 
epidemiological and clinical studies, instead it is more common to focus on one life event 
only,(3) such as loss of a family member, or use modified and shortened rating scales.(21) In 
addition to life events, a number of other rating scales have been developed and applied to 
directly measure emotional distress, such as the Center for Epidemiologic Studies-Depression 
Scale and General Health Questionnaire.(22) Furthermore, several mental disorders with a 
confirmed link to psychological stress, including depression,(23) anxiety,(24) stress reaction 
and adjustment disorders,(25) are also commonly used as a proxy for psychological stress, at 
least in psycho-oncology research.(3)  
A comprehensive biological measurement for stress is generally lacking in the present 
literature of human studies.(2) However, the search for ideal stress biomarkers has not 
ceased. Compared to the rating scales, stress biomarkers could shed light on the underlying 
biological mechanisms and be less influenced by reporting bias.(26) The most popular 
biomarker for stress measurement to date is cortisol. The cortisol levels obtained from saliva, 
blood and urine profile the circadian rhythm and reflect short-term stress response, whereas 
cortisol levels obtained from hair or nails illustrate the average cortisol concentrations during 
a longer period of time and measure the chronic stress.(27) Other primary mediators in stress 
responses may also serve as stress “biomarkers”, including sympathetic activity, 
neurotransmitters, and inflammatory cytokines.(28) Secondary mediators, which represent 
the cumulative effects of the primary mediators on a specific target, have also been 
recommended as possible stress “biomarkers”, such as heart rate variability, blood pressure, 
waist-hip ratio, and glycosylated hemoglobin.(28) Of note, the signature of adrenergic 
pathways in tumor tissue may also correlate with stress levels, reported for depressive 
symptoms and low social support, among ovarian cancer patients.(29) Additionally, 
antibodies to latent viruses and vaccination responses to antigen exposure have been 
suggested as candidates to reflect the effect of stress on immune system.(30) However, none 
of these biomarkers is specific to stress response. For example, cortisol levels are also 
associated with physical activity and obesity. 
2.2 CERVICAL CANCER 
Cervical cancer is the fourth most common cancer in women, with about half a million new 
cases diagnosed annually worldwide.(31) The incidence of cervical cancer varies 
geographically, and is much higher in less developed regions. In 2015, with a total number of 
563 new cases and 163 deaths, cervical cancer was ranked as the 13th most common cancer 
among women in Sweden.(32) However, among women younger than 45, cervical cancer is 
the most, or the second most, common cancer type across 123 countries.(33)  
Typically, it takes years for cervical cancer to develop from precancerous lesions, which 
creates room for early detection by cervical screening. The conventional cytology (i.e., 
  5 
Papanicolaou test, also known as Pap smear) and liquid-based monolayer cytology are still 
the most popular methods for cervical screening. Cytological abnormality determined by 
cervical screening generally requires further investigation through colposcopy - the 
macroscopic examination of the cervix during a gynecological exam, sometimes including a 
biopsy. The histological diagnosis of the biopsy includes 1) cervical intraepithelial neoplasia 
grade 1-3 (CIN 1-3), or invasive squamous cervical cancer if the lesion originates from 
squamous epithelium (constitutes 90% cervical cancer); 2) cervical adenocarcinoma in situ or 
invasive cervical adenocarcinoma, if the lesion derives from glandular cells; or 3) normality. 
Annually around 20,000 Swedish women receive an abnormal screening result, and around 
3,300 women get a diagnosis of cervical cancer in situ, meaning that the dysplasia spans more 
than 2/3 of the full epithelium and is interchangeably used with CIN3 in Sweden.(34)  
In early stages, cervical cancer may be asymptomatic. Symptoms, such as abnormal vaginal 
bleeding, pain during sexual intercourse, or pelvic pain, commonly manifest later in the 
course of the disease. Treatment for CINs includes excision of the lesion (e.g. cervical 
conization) and destructive techniques such as laser vaporization. Regarding invasive cervical 
cancer, the surgical approach includes hysterectomy (removal of the entire uterus and part of 
the vagina) or trachelectomy (removal of the cervix and part of the vagina, but leaves the rest 
of the uterus intact) for selected patients. Radiation therapy and chemotherapy are demanded 
for more advanced cases. During 1990-2001, the 5-year relative survival of cervical cancer 
was about 95% for screening-detected cervical cancer, and 69% for symptomatic cancers, in 
Sweden.(35) 
Risk Factors 
HPV infection has been recognized as a necessary but insufficient cause in cervical 
carcinogenesis.(6) HPV is a diverse family of viruses with over 170 types, and it is 
transmitted primarily through sexual activity. Most women (75%-80%) contract HPV at 
some point during their lives, and about 90% of infections are cleared spontaneously within 
1-2 years and only very few develop cervical cancer.(36) Among many HPV types, however, 
only 13 types are classified as oncogenic types, known as high-risk HPV.(37) Notably, 
HPV16 and HPV18 account for roughly 70% of all cervical cancer cases.(7) Growing 
evidence also suggests that persistence of HPV infection plays a key role in the malignant 
transformation.(7) However, the natural history of HPV infections remains largely unknown 
to date.(38). For instance, it is unclear if the observed “persistent” infection is due to 
continuously active HPV infection, reappearance after an undetectable state of viral latency, 
or by a re-infection. Several other factors have also been suggested to contribute the 
progression of HPV infection, including high-risk HPV types, viral load, and oncogene 
integration.(39) 
Other risk factors, for example smoking, use of hormonal contraceptives, and high-risk sexual 
behavior, might also contribute to cervical carcinogenesis. Tobacco smoking is associated 
with a 60% increased risk of cervical squamous cell carcinoma (both invasive and in situ) 
compared to never-smokers, and the risk elevates further by increasing number of cigarettes 
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smoked per day.(40) Long-term hormonal contraceptives use (>5 years) has been associated 
with a double risk for cervical cancer.(41) Although debated, early age at sexual debut 
(typically before the age of 14) has been suggested to increase the risk of cervical cancer.(42) 
Women with six or more sexual partners have three times higher risk of cervical cancer, 
compared with women with only one partner.(42) High parity has been suggested as a risk 
factor for cervical cancer, mainly in less developed countries. The risk increase is however 
only pronounced among women with >7 full-term pregnancies.(43) 
Of note, many risk factors may interact with HPV infection in modulating the risk of cervical 
cancer, rather than leading the carcinogenesis themselves. For example, instead of being 
directly carcinogenic to the cervix, oral contraceptive might make cervical mucosa vulnerable 
to HPV infection due to hormonal influence and subsequently contribute excess risk for 
cervical cancer. 
Prognostic Factors 
Clinical characteristics, such as tumor stage and pathological features, are the most important 
indicators for cervical cancer prognosis to date. The stage of cervical cancer is determined 
clinically at the time of primary diagnosis, mainly based on tumor size and its potential 
spread to the pelvis. The International Federation of Gynecology and Obstetrics (FIGO) 
staging system is most widely used. Five-year survival approaches 100% for microinvasive 
and 70-85% for localized cervical cancer.(44) Surgical staging may help improve the 
prediction by examining adverse pathological characteristics, including lymph node 
metastases, depth of cervical invasion, and involvement of lymph-vascular space. Certain 
histological subtypes, such as adenosquamous carcinoma and small-cell carcinoma with 
neuroendocrine features, constituting around 5% of cervical cancers, are associated with 
poorer prognosis.(44) 
HPV status and infection activity is a potential predictor for cervical cancer survival. In 
general, HPV infection indicates a favorable prognosis in patients with cervical cancer, even 
when controlled for clinical characteristics.(45,46) Conflicting results, however, exist 
between infections of different HPV types. Several studies reported that HPV18 positive 
cervical cancer was associated with poorer prognosis after primary treatment compared to 
HPV16 positive cancer, whereas others indicated HPV16 positivity actually predicted worse 
outcomes compared to HPV18 positivity.(47,48) It is plausible that viral oncoproteins, 
encoded by E6 and E7 genes from high-risk HPVs, inactivate the tumor suppressor gene (e.g. 
p53) and therefore account for the different clinical courses. Although less discussed, 
overexpression of vascular endothelial growth factor, epidermal growth factor receptor, 
cyclooxygenase-2 and tumor hypoxia have also been suggested to be potentially able to 
predict cervical cancer outcomes.(47) 
2.3 PROSTATE CANCER 
Prostate cancer is the most common cancer among men in Europe and the US, and the second 
most common cancer among men in the world.(31) In 2012, over one million men were 
  7 
diagnosed with prostate cancer globally. Almost all prostate cancers occur over the age of 50 
(99.9%) (49) and are adenocarcinomas originating from prostatic epithelial cells (95%).(50) 
Early prostate cancer hardly ever manifests symptoms. Later in the course of disease, early 
symptoms include frequent urination, difficulty to urinate in a steady stream, painful 
urination, and blood in the urine. Late symptoms such as bone pain may emerge when the 
cancer has spread out of the prostate, often to the spine, hips and ribs. 
Prostate cancer usually grows slowly and one can live with prostate cancer for years without 
perceiving any symptom. Men recently diagnosed with prostate cancer are more likely to die 
from another cause, such as cardiovascular disease, than from prostate cancer.(51) About one 
third of Swedish patients and 11% of US patients died from their prostate cancer within 5 
years after diagnosis from 1961/1973 through 2008.(51) There were 307,000 prostate cancer 
deaths worldwide in 2012, making prostate cancer the fifth leading cause of cancer-related 
death in men.(31)  
It is of paramount importance to distinguish lethal or aggressive prostate cancer from 
relatively benign ones at the time of diagnosis, because many low-risk cases could be safely 
managed with active surveillance or watchful waiting.(52) According to clinical guidelines, 
physicians evaluate tumor characteristics, predicted prognosis, life expectancy, and individual 
preferences when tailoring individual treatment plan for prostate cancer.(53) Current 
treatment options include, but are not limited to, surgery, radiation therapy, hormone therapy, 
and chemotherapy. 
Risk Factors 
The etiology of prostate cancer remains enigmatic and poorly understood. Genetics, as well 
as dietary and lifestyle factors, have been suggested as primary contributors to the risk of 
prostate cancer. Other established risk factors include age and androgens.  
Familial clustering of prostate cancer was first reported in 1956.(54) In 2000, the Nordic twin 
cohort indicated that genetic factors explained 42% variants in the liability of developing 
prostate cancer.(55) More recently, the expanded Nordic twin cohort, using novel statistical 
strategies, suggested even higher genetic contribution to the disease risk (58%).(56) Genome-
wide association studies have identified more than 90 common single-nucleotide 
polymorphisms (SNPs) related to the susceptibility for prostate cancer, which are estimated to 
explain about 30% of the familial risk for prostate cancer.(57)  
The apparent geographic variation in prostate cancer incidence and the remarkably increased 
prostate cancer risk in migrants moving from low-incidence to high-incidence countries 
support the contribution of environmental factors to prostate cancer development.(58) A 
number of dietary agents, such as fat, red and processed meat, vitamin E, have been 
associated with prostate carcinogenesis.(58) However, few findings have been confirmed in 
large chemoprevention studies.(58) Higher physical activity is suggested to be associated 
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with 10% lower risk of prostate cancer,(59) and higher body mass index is related to 
increased risk of advanced prostate cancer.(60)  
Prognostic Factors 
Many localized cancers are slow-growing regardless of treatment,(61) whereas others 
develop metastases despite surgical treatment.(62) Nomogram based on Gleason scores, 
tumor stage and pretreatment prostate-specific antigen (PSA) levels has been developed to 
predict the prognosis(63). However, they cannot completely explain the biological 
heterogeneity of prostate cancer regarding survival. Although the potential roles of variation 
in genes and gene expressions are much less established in relation to lethal outcome,(64,65) 
a handful of biomarkers have been identified for prostate cancer progression. 
Gleason score 
Gleason score is a widely-used system to evaluate prostate tumor grade. It is scored from 1 to 
5 according to the histological pattern of differentiation and arrangement of tumor cells in 
hematoxylin and eosin stained sections. The Gleason patterns 4 and 5 predict poor prognosis. 
Two most dominant patterns are scored and summed to comprise the Gleason score ranging 
from 2 to 10. Gleason grade has been demonstrated to have a good correlation with the 
prostate cancer prognosis and is one of the most powerful predictors.(66) 
Tumor stage 
The prognostic classification and selection of treatment are highly dependent on tumor stage, 
which can be determined either by clinical stage or pathological stage. Studies have shown 
that both clinical and pathological stage are reliable predictors for prostate cancer survival 
after radical prostatectomy(67), and most of the localized cancers have a relatively benign 
course even without initial treatment.(61)  
Biological markers 
PSA, a glycoprotein enzyme released by the epithelial cells of the prostate gland, is present in 
small amount in the blood of healthy men but often rises in prostate cancer or other prostate 
diseases. PSA can provide information for screening (under debate), diagnosing, monitoring 
treatment response and recurrence for prostate cancer.(68) However, whether PSA is 
predictive for long-term survival independent of tumor grade and stage requires further 
investigation.(69) 
Ki-67 is one of the cell-cycle-regulating proteins and expressed in every phase of the cell 
cycle, except in resting cells. The Ki-67 index (the percentage of positive nuclei in 
immunohistochemistry staining) has been used as a reliable biomarker to measure cell 
proliferation. Consistent evidence has shown that Ki-67 is associated with disease 
progression and survival in prostate cancer.(69) However, given its relatively low expression 
in preoperative biopsies, Ki-67 might not be as effective as the other aforementioned classic 
factors in prognosis prediction.(69) 
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Angiogenesis plays a pivotal role in carcinogenesis by providing nutrients and oxygen for 
tumor growth, as well as direct access to vasculature for metastasis. Microvessel density, a 
measure of the extent of neoangiogenesis, has been suggested to be a predictor for prostate 
cancer survival by some, but not all, studies.(69) Other morphological features of 
angiogenesis, e.g. smaller vessel size and greater irregularity of vessel lumen, might also 
predict prostate cancer mortality.(70)  
Apoptosis, the programed cell death, is commonly visualized by using terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays to detect DNA 
fragmentation. The balance between apoptosis and proliferation determines the rate of tumor 
growth. Decreased apoptosis has been associated with the recurrence of prostate cancer.(71)  
Perineural invasion, the presence of cancer cells surrounding nerves fibers, is an adverse 
pathologic characteristic reported on prostate biopsy specimens. The perineural space is 
believed to serve as a path of decreased resistance for tumor cells spreading. Convincing 
evidence has suggested that perineural invasion in prostate biopsies is a promising 
prognosticator for prostate cancer.(72) However, controversy still exists whether perineural 
invasion predicts disease recurrence and survival independently from PSA level and Gleason 
score.(73,74) 
The promoter region of transmembrane protease serine 2 (TMPRSS2) gene commonly fuses 
with the coding region of v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) 
gene – a member of the erythroblast transformation-specific family of transcription factors – 
in prostate cancer.(75) TMPRSS2-ERG gene fusion upregulates the expression of ERG, and 
has been associated with poorer survival among prostate cancer patients in a watchful waiting 
setting,(76) but not in alternative settings.(77)  
2.4 PSYCHOLOGICAL STRESS AND CANCER 
Among a number of health consequences potentially related to stress, the potential link of 
stress and cancer has been elusive for centuries. Galen, the ancient Greek physician, observed 
that women with the “melancholic” temperament was more likely to develop cancer than 
women with the “sanguine” temperament.(3) The body of literature on the association 
between stress and cancer has been dramatically growing during the past 40 years. The 
question, however, remains unanswered.(2) Bert Garssen reviewed the existing findings and 
summarized a few reasons for the lack of conclusion to date. Many studies were small in size 
and therefore unable to distinguish the presumably mild effect of stress on cancer from null. 
The type of cancer is likely highly relevant in this regard – cancers that are of immunological 
origin or with poor prognosis might be more susceptible to stress. Most studies also lacked 
control for confounders, such as behavioral factors.(2) A true biological link between stress 
and cancer is however still highly plausible, given the increasingly strong evidence between 
stress and cancer progression.(3) Pooling available prospective cohort studies, Chida and 
colleagues quantified the effect-size of psychosocial factors on cancer incidence (Hazard ratio 
[HR] 1.06, 95% confidence interval [CI] 1.02 to 1.11) and cancer progression (HR 1.03, 95% 
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CI 1.02 to 1.04) in general.(3) Provided with the potential publication bias as noted, the effect 
size of psychological stress on cancer incidence and progression is presumably small.(3) The 
associations are however stronger, in well-designed studies, for certain stressors (e.g. life 
stressor for cancer progression), as well as for certain cancer types (e.g. lung cancer). In 
parallel with human findings,  new evidence has been accumulating from animal studies 
shedding light on the biological plausibility underlying the stress-cancer link.(78)  
Table 1. Prospective studies investigating the link between psychological stress and 
cervical cancer. 
Study Country/ 
region 
Participants Follow-up 
(years) 
Stressor Effect size 
Incidence      
Chang 2015 South 
Korea 
601,775 19 (mean) Major depression 
Minor depression 
Chronic depression 
0.72 (0.52-0.98) 
1.10 (0.91-1.33) 
0.52 (0.30-0.91) 
Dalton 2008 Denmark 3,218,440 8 (mean) Divorce 
Depression 
1.90, significant 
1.00, non-significant 
Fang 2011 Sweden 4,687,073 0-15 Death of child 1.46 (1.17-1.80) 
Goldacre 2007 UK 577,546 0-36 Depression  
Anxiety 
0.82 (0.51-1.27) 
0.85 (0.53-1.30) 
Hung 2014 Taiwan 20,033 9 (mean) Depression 1.02 (0.55-1.90) 
Ikeda 2013 Japan 44,152 12 (mean) Social support “no significant 
association” 
Johansen 1997 Denmark 11,231 25 (mean) Cancer in a child 1.1 (0.9-1.4) 
Kennedy 2014 Sweden 4,219,691 0-40 Death of parent, before/ 
after age 18 
1.4 (1.1-1.6) 
1.0 (0.9-1.1) 
Kvikstad 1994 Norway 51,695 0-24 Death of spouse 1.04 (0.80-1.35) 
    Divorce 1.44 (1.30-1.60) 
Kvikstad 1996 Norway 44,419 0-26 Death of child 1.11 (0.92-1.35) 
Shen 2013 Taiwan 19,793 2-6 Anxiety 0.93 (0.54-1.50) 
Survival      
Kvikstad 1995 Norway 2,336 6 (mean) Divorce 1.25 (0.99-1.57) 
  1,839 6 (mean) Death of spouse 1.59 (0.65-3.89) 
Kvikstad 1996 Norway 2,674 0-26 Death of child 1.14 (0.72-1.82) 
Li 2003 Denmark 513 1-18 Death of child 1.33 (0.60-2.95) 
Stress and Cervical Cancer 
Several,(79-81) but not all,(82-85) clinical studies have suggested an association between 
psychological stress and cervical dysplasia. The findings on the incidence of invasive cervical 
cancer are also inconclusive, particularly for the associations of stress-related mental 
disorders (Table 1).(8,86-95) However, the limited evidence from stressful life events (e.g. 
loss of a family member and divorce) tends to be consistent. All of the six prospective studies 
are from Nordic countries and assessed the effect of a specific life event.(8,87,88,92-94), and 
none of them controlled for potential behavioral or lifestyle factors. The impact of different 
life events might vary – for instance, divorce appears to have a greater impact on cervical 
cancer risk than widowhood.(94) Moreover, the impact might vary by different ages at 
exposure – for example, loss of a parent was more likely to affect women in their early lives 
in terms of cervical cancer risk.(93)  
Regarding survival, the evidence is rather scarce (Table 1).(8-10) Three prospective studies 
suggested that life events were likely associated with an unfavorable prognosis in cervical 
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cancer, although none of them held enough power to draw a firm conclusion. Future studies 
linking stress to both incidence and survival of cervical cancer are warranted. 
Table 2. Prospective studies investigated the link between psychological stress and 
prostate cancer. 
Study Country/ 
region 
Participants Follow-up 
(years) 
Stressor Effect size 
Incidence      
Chen 2016 Taiwan 58,603 5 Anxiety 4.67 (3.06-7.12) 
Dalton 2008 Denmark 3,218,440 8 (mean) Divorce 
Depression 
0.97, non-significant 
0.93, non-significant 
Gallo 2000 USA 804 13 Depression 11.8 (1.00-144.3) 
Goldacre 2007 UK 577,546 0-36 Depression  
Anxiety 
0.69 (0.47-0.97) 
0.70 (0.47-0.99) 
Gross 2010 USA 3,177 24 Major depression 1.09 (0.14-8.73) 
Heikkilä 2013* Europe 53,773 12(mean) Job strain 0.86 (0.68-1.09) 
Hung 2014 Taiwan 20,033 9 (mean) Depression 2.88 (1.96-4.26) 
Ikeda 2013 Japan 44,152 12 (mean) Social support “no significant 
association” 
Johansen 1997 Denmark 11,231 25 (mean) Cancer in a child 1.0 (0.8-1.2) 
Keinan-Boker 
2009 
Israel  2,249,462 0-22 World War II, before/  
after PSA era 
0.47 – 0.75 
1.02 – 1.34 
Kubo 2006 Japan 14,052 8 (mean)  Rotating shift work 3.00 (1.20-7.70) 
Lemogne 2013 France 14,203 15 (mean) Sick leave for depression 
Depressive symptoms 
Chronic depression 
1.39 (0.79-2.43) 
0.99 (0.86-1.13) 
0.60 (0.38-0.96) 
Liang 2011 Taiwan 75,771 Unkown Depression 1.33 (0.79-2.23) 
Metcalfe 2007 Scotland 5,743 31-34 Medium daily stress 
High daily stress 
1.65 (1.20-2.27) 
1.35 (0.87-2.10) 
Nielsen 2007 Demark 5,496 19-21 Daily stress 0.99 (0.90-1.09) 
    Divorce 0.92 (0.51-1.67) 
    Death of spouse 1.09 (0.59-2.03) 
Penninx 1998 USA 1,708 3.8 (mean) Chronic depressive mood 1.47 (0.20-10.8) 
Shen 2013 Taiwan 19,793 2-6 Anxiety 2.17 (1.56-2.93) 
Survival      
Jan 2016 Sweden 4,105 4.3 (mean) High daily stress 
Often grieving from loss  
1.66 (1.05-2.63) 
1.90 (0.93-3.87) 
Li 2003 Denmark 116 1-18 Death of child 4.99 (0.72-34.76) 
Prasad 2014 USA 103,809 0-6 Depression 1.16-1.86 
* A meta-analysis pooled 12 European cohorts from Denmark, Finland, France, Netherlands, Sweden and UK. 
Stress and Prostate Cancer 
Investigating the true incidence of prostate cancer is practically difficult after the introduction 
of PSA, because of the variable accessibility to PSA screening. To date there are 17 
prospective studies or meta-analyses examining the association between psychosocial factors 
and prostate cancer incidence (Table 2).(87,89-92,95-106) The findings are conflicting – for 
example a large pooled meta-analysis showed that work stress was likely associated with a 
lower risk of prostate cancer,(99) whereas another cohort indicated that shift workers were at 
3-fold risk of prostate cancer.(101) Although the findings were not statistically significant, 
two other studies have shown largely opposite associations of daily stress with the risk of 
prostate cancer.(104,105) The significant associations were also opposite for 
depression(87,89,90,102) and anxiety.(89,95,96) The discrepancy of findings before and after 
PSA era may suggest a potential contribution of screening seeking behaviors to prostate 
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cancer detection. For example, exposure to severer stressors might entail different health 
consciousness and willingness to seek for medical counseling, leading to different use of PSA 
screening and different incidence of prostate cancer.(100)  
On the other hand, to the best of our knowledge, only three prospective studies examined the 
potential role of psychological stress on prostate cancer survival.(10,107,108) Despite limited 
evidence, the findings are consistent across a range of stressors. However, only one study 
took into account the impact of competing risks on these findings,(107) as for example 
psychological stress is rather consistently related to a higher risk of cardiovascular mortality 
among prostate cancer patients.(109)              
Major Biological Mechanisms 
Several potential biological mechanisms have been proposed for the link between 
psychological stress and carcinogenesis.(5) Given the pivotal role of SNS and HPA axis in 
stress system, two major pathways, i.e. adrenergic and glucocorticoid pathways, have drawn 
considerable attention. Both SNS and HPV axis exert profound influences on immune 
regulation, suggesting another important pathway through stress-induced immunosuppression 
and oncogenic infection. Although less investigated, other neuroendocrine transmitters 
potentially affected by psychological stress have also been suggested for altered cancer 
progression. For instance, serotonin promotes tumor cell growth and angiogenesis,(110) 
whereas dopamine exerts opposite actions.(111)    
Adrenergic pathway 
Emerging evidence has illustrated that the activation of SNS promotes cancer progression 
through tumor growth, dissemination, angiogenesis, malignant transformation, macrophage 
infiltration, and inflammation.(11) β-adrenergic receptors, G-protein-coupled receptors, 
mediate most of the effects of stress hormone catecholamine released by SNS. Adrenergic 
receptor beta 2 (ADRB2)  is the dominant adrenergic receptor which has been identified on 
several types of cancer cells, including prostate cancer.(112) β-adrenergic receptors transmit 
the information from the extracellular environment to the inside of the cell and subsequently 
increase the intracellular level of cAMP that activates cAMP-dependent protein kinase 
(PKA). The downstream cAMP-responsive-element-binding (CREB) protein is either directly 
activated by PKA or through serine/threonine-protein kinase PAK4, and has been linked to 
tumor cell proliferation, dissemination, angiogenesis, as well as inhibition of apoptosis.(5) 
Moreover, by inhibiting the ras homology family member A, PKA induces neuroendocrine 
differentiation in prostate cancer cell lines, although evidence remains scarce in vivo.(112) 
Furthermore, through regulating CREB, the ADRB2/cAMP/PKA signaling pathway 
stimulates the androgen receptor responsive gene transcription and eventually modulates the 
activity of androgen receptors,(113) which is an established mechanism specifically involved 
in prostate cancer development. Lastly, although debated (114), results from two large 
observational studies suggested that use of β–adrenergic receptor blocking agents may 
improve cancer-specific survival among prostate cancer patients (115,116). 
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Glucocorticoid pathway 
Glucocorticoid receptor, a member of the nuclear receptor family, is the cognate binding 
protein to the glucocorticoids released by HPA axis. Its activation regulates a great deal of 
biological processes, such as metabolism, growth and cellular apoptosis. Accumulating data 
substantially supports the role of glucocorticoid signaling in the progression of solid tumor 
through increased cell proliferation, inhibited apoptosis and DNA repair activity.(4,117) 
Glucocorticoid also has the potential to induce chemotherapy resistance by blocking tumor 
cell death,(117) although cortisol is routinely administered through chemotherapy for 
potential nausea and allergic reactions. As a result of chronic stress, flattened diurnal cortisol 
rhythms and elevated nocturnal cortisol have been commonly noted among cancer patients, 
particularly patients with advanced stages of disease.(118,119) The altered cortisol patterns 
may, in part, reflect the distress status,(120) and/or avoidant coping.(121) In addition, the 
flattened cortisol slope has been linked to compromised survival in several cancer 
populations, including breast, lung, and renal cell cancers.(118,122,123) 
Immunosuppression and viral oncogenesis 
The SNS and HPA axis work hand-in-hand in effecting the immune response: both 
catecholamine and glucocorticoids regulate different aspects of immune function, including 
antigen presentation, T-cell proliferation, cell-mediated and humoral immunity.(5) For 
example, chronic stress may induce lymphocyte reduction mediated through increased Fas 
receptor expression.(124) In general, compromised cellular immunity induced by chronic 
stress assists tumor initiation and progression.(5) The role of stress-induced 
immunosuppression is, therefore, possibly substantial in infection-related cancer in particular. 
That said, impaired cellular immunity might indirectly lead to a higher risk of oncogenic viral 
infection and DNA damage.(124) In fact, the first experimental demonstration of stress and 
cancer was based on tumor viruses in mouse models.(125) It has been shown that several 
human tumor viruses, including HPV16 and 33, are sensitive to the signaling pathways 
activated by catecholamine and/or glucocorticoids. As a result, stress hormones could 
reactivate latent tumor viruses, stimulate expression of viral oncogenes, and inhibit antiviral 
responses in the host. For example, in response to glucocorticoids, high-risk HPVs activate 
gene expression,(126,127) interact with cellular proto-oncogenes,(128) and evade cellular 
immune response through down-regulating the expression of class I human leukocyte 
antigens.(129) Conversely, glucocorticoid antagonists suppressed the HPV activity in cell 
lines.(130,131) 
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3 AIMS 
The overall aim of this thesis was to investigate the potential impact of psychological stress 
on cancer initiation and progression, using cervical cancer as an example, as well as to 
understand the mechanistic contributions of immune and neuroendocrine systems to this link 
in cervical and prostate cancers. 
The specific aims were: 
• To assess the potential associations of loss of a family member, as an extremely 
stressful life event, with the risks of HPV infection, cervical dysplasia, and invasive 
cervical cancer. 
• To estimate the impact of psychological stress, using stress-related mental disorders 
and stressful life events as proxies, on the cancer-specific survival among patients 
with cervical cancer. 
• To demonstrate the differential signaling of stress-related molecular pathways in 
tumor tissue of US men with lethal prostate cancer, compared with men with 
nonlethal disease.  
• To further verify the differential expression of genes in stress-related pathways 
between lethal and nonlethal prostate cancer among Swedish men with localized 
disease, and to explore whether genetic variants could explain the potential 
differences.  
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4 STUDY MATERIALS 
4.1 SWEDISH DATA SOURCES 
4.1.1 Swedish public and health registers 
Sweden is well-known for having nationwide and high-quality registers in public and health 
data. Every resident in Sweden is assigned a unique personal identification number, which 
allows the cross-linkage of data through all Swedish public and health registers. In this thesis, 
we took the advantage of several major registers in Sweden to measure the indicators for 
psychological stress, cancer incidence and survival, as well as to identify the demographic 
characteristics through cross-linkages. 
The Swedish Multi-Generation Register documents parental information on Swedish 
residents who were born from 1932 onward and alive in 1961.(132) Information on both 
biological and adoptive parents are available, and the coverage reaches 97% for mothers and 
95% for fathers. With the parental information, the family linkage can be largely extended to 
other family members, such as children, spouses (confined to those with a registered common 
child), and siblings, of the index persons. 
The Swedish Causes of Death Register comprises of the death certificates of all Swedish 
residents since 1911. The death certificate is compulsory for all deaths, and filled out by the 
physicians in charge during the last hospitalization, or by a family physician or medical 
examiners if death occurs outside of the hospital. The underlying cause of death is recorded 
in the register, and is considered as a valid source of information for studies of many diseases, 
including cancer.(133)  
The Swedish Patient Register has collected records of hospital discharge diagnosis since 
1964/1965, and covered 60% of the entire country in 1969, 85% in 1983, and 100% from 
1987 onward.(134) The primary and secondary diagnoses are coded according to the Swedish 
versions of International Classification of Disease (ICD) system (ICD-7, before 1969; ICD-8, 
1969-1986; ICD-9, 1987-1996; and ICD-10, from 1997). From 2001, the collection is 
expanded to hospital-based outpatient visits with a coverage of >80%. The register has been 
validated for many diseases and regarded as a reliable source for clinical diagnosis in 
general.(134) 
The Swedish Cancer Register was established in 1958 to collect all malignancies and certain 
benign tumors diagnosed in Sweden.(135) Health care providers are requested to report any 
newly detected cancer to the register by law. The completeness is therefore virtually 100%. 
Besides cancer site, information on histology and tumor stage is also largely available from 
2004 in the register. 
The Longitudinal Integration Database for Health Insurance and Labor Market Studies (LISA 
by Swedish acronym) includes all Swedish residents aged 16 years and older since 1990. It 
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integrates information on marital status, employment, income, education level, etc., from the 
social and educational sectors as well as labor markets on a yearly basis.  
Other nationwide public registers were also linked to identify demographic information, for 
instance country of birth through the Total Population Register, and, to determine the end of 
follow-up, for example on the date of emigration through the Migration Register.  
4.1.2 Swedish National Cervical Screening Registry (NKCx by Swedish 
acronym) 
Cervical screening was introduced to Sweden in the mid-1960s and the organized screening 
program was initiated in 1970s. Initially, women aged 30 to 49 (later 25 to 49) years were 
invited to screening every 3 to 4 years. From 1998, all women aged 23 to 50 are invited to 
screening in every third year and those aged 51 to 60 in every fifth year.(136) The NKCx has 
collected cervical screening records through both organized and opportunistic screening from 
1969, and became nationwide since 1995.(137) 
4.1.3 Two population-based studies of HPV infection and cervical cancer 
The National Cervical Screening Register (NCSR) Study aimed to investigate the HPV 
infection in relation to cervical cancer risk, based on 1,431,723 women whose first registered 
smear was classified as cytologically normal in six Swedish counties during 1969-
2002.(138,139) It included 1,360 women diagnosed with in situ or invasive cervical cancer 
(i.e. cases) and 1,360 controls randomly selected using incidence density sampling and 
matched to the case women on county of residence, age and calendar date of first normal 
smear registered. 
With a similar purpose, the Uppsala Study was based on 146,889 women who lived in 
Uppsala county and participated in the cervical screening at least once during 1969-
1995.(140) Among women with a first registered smear of clear result, 478 women diagnosed 
with in situ cervical cancer were enrolled as cases and 608 controls matched to the cases on 
age and calendar date of the first normal smear were randomly selected from the study base 
using incidence density sampling.  
For both studies, all available smears during the study period, from included case and control 
women, were obtained from the county laboratories and tested for HPV infection. In the 
NCSR study, DNA was extracted from the archival smears using a validated method 
described elsewhere(141) and amplified by polymerase chain reaction (PCR).(142) The 23 
types of HPV including HPV16 were then determined through a PCR enzyme 
immunosorbent assay and reverse dot blot hybridization procedure(143), or a multiplex 
fluorescent bead-based assay.(142) Among HPV16 positive samples, the absolute number of 
viral copies of the E7 gene per microliter were quantified as the viral load according to the 
Taqman real-time quantitative PCR.(144) All analyses were performed by the WHO HPV 
LabNet Global Reference Laboratory, Malmö, Sweden and blinded to the sample information. 
For the Uppsala Study, DNA extraction was done using the same method and HPV16 was 
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detected using a specific fluorescent hybridization probe based on the Taqman real-time 
quantitative PCR.(145) A certain number of PCR cycles were required to reach the threshold 
of accumulating fluorescence beyond the background level. The threshold cycle value was 
therefore calculated in HPV16 positive smears as an estimate of viral load, which is inversely 
correlated with the initial number of viral copies in the sample (i.e., the lower the threshold 
cycle value, the higher the viral load). All HPV16 analyses were done at the Department of 
Medical Genetics in Uppsala and blinded to clinical information. 
For the Uppsala Study, information on lifestyle factors including smoking, sexual behaviors, 
use of oral contraceptives, parity, and abortion, was collected for 90% of participants using a 
comprehensive questionnaire through telephone interview.(146) 
4.1.4 National Cervical Cancer Audit 
The National Cervical Cancer Audit included all newly diagnosed cervical cancer cases in 
Sweden from 2002 through 2011. Originally, 4,646 women with an invasive cervical or 
unspecified uterine cancer(147) were identified from the Swedish Cancer Register. After 
reviewing the archived histological specimens, 4,269 women were included in this cohort. 
Clinical information on tumor stage, histology, mode of detection, primary treatment, and 
adjuvant therapy was collected through reviewing corresponding medical records. 
4.1.5 Swedish Watchful Waiting Cohort 
The Swedish Watchful Waiting Cohort consisted of 1,367 men who underwent trans-urethral 
resection of the prostate (TURP) for symptomatic benign prostatic hyperplasia and were 
incidentally diagnosed with localized prostate cancer in the Örebro and South East Health 
Care Regions in Sweden during 1977-1998.(65) The population-based prostate cancer quality 
registers operating in these regions were used to identify eligible cases. The specimens of 
tumor tissue were available for 1,256 men, and these were re-reviewed for cancer 
confirmation. According to the standard treatment plan at that time, all men were followed 
expectantly without initial treatment until disease progress, namely watchful waiting.  
4.2 US DATA SOURCE 
The Physician’s Health Study (PHS) was a randomized control trial involving 29,067 US 
male physicians from 1982, originally aimed to prevent cardiovascular disease and 
cancer.(148) The Health Professionals Follow-up Study (HPFS) is an ongoing prospective 
cohort initiated in 1986, which is comprised of 51,529 US male health professionals. Its 
primary purpose is to identify the causes of heart disease and cancer.(149) The PHS and 
HPFS Prostate Tumor Tissue Cohort was nested within PHS and HPFS. As a result, 3,108 
men with histologically confirmed prostate cancer were eligible for inclusion. Tumor 
specimens from prostatectomy and TURP were available for 2,200 participants, whereas the 
specimens through biopsy were not included. 
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5 STUDY DESIGN AND METHODS 
5.1 BEREAVEMENT, HPV INFECTION, AND CERVICAL CARCINOGENESIS 
(PAPER I) 
We included 2,466,107 women who were born in Sweden from 1932 onward and were 
registered for at least one Pap smear in the NKCx between 1969 and 2011 (Figure 1). We 
followed all women from January 1st 1969 or birth, whichever came later, until a first 
diagnosis of in situ or invasive cervical cancer, total hysterectomy, death, emigration, or 
December 31st, 2011, whichever occurred first. 
During the follow-up, 14,011,269 registered smears were identified. Based on the age at 
smear and elapsed time from the latest smear, we calculated the degree of screening 
participation as previously described.(150) In brief, we divided the actual participation years 
by the sum of years scheduled for screening, until the first registered abnormal cytology. 
Subsequently we classified the screening adherence into five categories, namely the quartiles 
of the calculated degree of participation as well as the “unscreened” (i.e., only registered with 
opportunistic smears through the entire study period). 
We carried out three parallel analyses to examine the associations of loss of a family member 
– one of the extremely stressful life events – with HPV infection, first abnormal cytology, in 
situ and invasive cancers. 
5.1.1 HPV infection 
In the NCSR Study and the Uppsala Study, the control women were randomly selected from 
the cervical screening participating population in different Swedish counties and had no in 
situ or invasive cervical cancer during respective study periods. We linked these control 
women to our study base, namely the NKCx, and identified 1,770 women with 4,987 smears 
that were eligible for inclusion (Figure 1). After excluding smears with poor cellularity 
(N=515) and repeated smears of the same workup (N=439), we finally included 1,696 
women with 4,033 smears for the analysis of HPV16 infection. The repeated smears were 
defined as consecutive smears with elapsed time from the first smear of less than one year, 
assuming that the following smears were possibly a part of the same diagnostic workup. 
Among 4,033 smears tested for HPV16, there were 3,830 HPV16 negative and 203 positive 
smears, of which 160 were further measured for HPV16 viral load(138,140) and were 
subdivided into high or low level according to the median viral load value. Due to the 
observed batch effect, the cut-off values were estimated both per calendar period of sampling 
(1969-1984, 1985-1989, 1990-1994, or 1995-2005) and per calendar period of test (2005-
2007 or 2008-2009) in the NCSR Study. HPV16 positive and negative smears were treated as 
case and control smears in this analysis. 
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Figure 1. The flow chart of Paper I. CC, cervical cancer; HPV, Human papillomavirus; NCSR, 
National Cervical Screening Register; SNOMED, the systematized nomenclature of medical diagnoses defined 
by Swedish Association for Clinical Cytology; VL, viral load. 
 
In addition to HPV16, smears from the NCSR Study were also tested for 21 additional HPV 
types, including15 high-risk and six low-risk types (Figure 1). 2,046 of 2,464 (83%) smears 
were thereby classified to any positive or all negative smears in terms of all HPV types tested, 
and used as case and control smears in this analysis, respectively. We further defined smears 
with a positive detection of any low-risk or high-risk HPV type as low-risk or high-risk HPV 
infection, respectively. In some smears, low-risk and high-risk HPV types were concurrent.  
5.1.2 Abnormal cytology 
Cytological diagnosis on smears was available in the NKCx and coded in the systematized 
nomenclature of medical diagnoses (SNOMED) by the Swedish Society of Clinical 
Cytology. We, therefore, defined the abnormal cytology as a smear with a cytological 
Exclusion:
• 3,418,733	smears	 from	954,881	women	born	before	1932	
or	outside	of	Sweden;
• 959,426	smears	from	125,536	women	after	cervical	cancer	
diagnosis;
• 119,940	smears	from	47,266	women	after	total	
hysterectomy;
• 375,809	smears	from	93,208	women	after	emigration;
• 269	smears	from	161	women	of	incorrect	sampling	date.
Swedish	National	Cervical	Screening	
Register	(1969-2011)
3,529,914	women	and	18,885,446	smears
Study	Base
2,466,107	women	and	14,011,269	smears
In	Situ and	Invasive	Cervical	
Cancer
75,128	in	situ and	invasive	
cervical	cancer	and	375,640	
matched	control	women	
390,310	first	abnormal	
cytology	and	1,951,319	
matched	normal	cytology	
Exclusion:
• Poor	quality	(SNOMED	
M09005/M09010/M09019;	
N=1,519,496);
• Incorrect	SNOMED	code	
(N=2,507).
Abnormal cytology
2,410,284	women	and	
12,489,266	cytology
Exclusion:	17	unmatched	atypia (+)
NCSR	Study	(1969-2002)
Uppsala	Study	(1969-1995)
1,770	CC-free	women	and	4,987	smears
276	any	HPV	positive	and	
1,770	any	HPV	negative
HPV	Infection
1,696	CC-free	women	and	
4,033	smears	tested	for	HPV
Exclusion:
• Poor	cellularity	(absence	of	β-
globin/	β-actin;	N=515);
• Sampling	interval	<	1	year	
(N=439).
203	HPV16	positive	and	
3,830	HPV16	negative
Exclusion:	43	smears	of	HPV16	
positive	were	not	tested	for	VL
126	low/	34	high	HPV16	VL	
and	3,830	HPV16	negative
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diagnosis of atypical, low-grade, or high-grade abnormality (Table 3). We identified the first 
abnormal smear (if any), i.e. the case smear, during the study period for each woman, and the 
follow-up was censored afterwards. Using incidence density sampling, we randomly selected 
five cytologically normal smears from other women per case smear, which were individually 
matched to the case smear by birth year and screening adherence. In total, we included 
390,310 first abnormal and 1,951,319 control smears (Figure 1). 
Table 3. Swedish standard cytology nomenclature. 
Classification Description SNOMED 
Sample quality Inadequate M09005, M09010 
 Endocervical cells lacking M09019 
Normal Normal M00110 
Atypical Atypical squamous cells of undetermined significance M69710 
 Atypical glandular cells of undetermined significance M69720 
Low-grade CIN 1 M74006 
 Koilocytosis M76700 
High-grade CIN 2 M74007 
 CIN 3 M80702 
 Squamous cell carcinoma M80703 
 Adenocarcinoma or adenocarcinoma in situ M81403 
 Atypia in cells of uncertain origin M69700 
 Atypical squamous cells – cannot exclude high-grade dysplasia M69719 
  Malignant neoplasm, unspecified M80003 
 Malignant neoplasm of uncertain origin M80009 
5.1.3 In situ and invasive cervical cancers 
Information on diagnosis of in situ and invasive cervical cancer was available through the 
linkage to the Swedish Cancer Register. In situ cancer comprised both carcinoma in situ 
(equivalent to CIN 3) and adenocarcinoma in situ. We identified the first diagnosis of 
histopathologically confirmed in situ or invasive cervical cancer during the follow-up for 
each woman (if any) and thereby defined the case women. Using incidence density sampling, 
we randomly selected five women without any cervical cancer per case woman, and they 
were individually matched to the case woman by birth year and screening adherence. In total, 
we obtained 69,674 in situ and 5,454 invasive cancers as well as 375,640 control women for 
this analysis (Figure 1). In the analysis of invasive cancer, we did not include the 300 
invasive cancers that were developed from the in situ cancer, because the follow-up for these 
women was censored at the diagnosis of in situ cancer.  
5.1.4 Bereavement 
Through the Swedish Multi-Generation Register, we identified the family members (i.e., 
parents, children, spouse, and siblings) for all women in the study base. Bereavement, namely 
loss of a family member due to death, was identified by linking all family members to the 
Swedish Causes of Death Register from 1961 to 2011. Any loss before the reference date, 
namely the date of smear for the analyses of HPV infection and abnormal cytology while the 
matched date for the analysis of in situ or invasive cervical cancer, was regarded as the 
exposure. We further classified the loss events into loss of a parent or loss of a child, spouse, 
or sibling, as well as loss due to natural or unnatural (namely self-harm or other injuries) 
 22 
cause of death. In addition, we divided the time since loss (namely the elapsed time from the 
date of latest loss to the reference date) into 1 year, 2 to 4 years, or ≥5 years. 
5.1.5 Lifestyle factors 
Lifestyle factors, such as smoking, high-risk sexual behavior, use of oral contraceptives, and 
high parity, may influence the associations of loss of a family member with risks of HPV 
infection and cervical cancer development. 469 control women in the Uppsala Study were 
invited to participate in a questionnaire interview, and 345 women completed the interview. 
We included these women with available information on such lifestyle factors, and compared 
the potential difference of lifestyle factors between women with and without loss using Chi-
square for categorical variables or Mann-Whitney U tests for continuous variables.  
5.1.6 Statistical analyses 
Analyses of HPV Infection 
We estimated the odds ratio (OR) of HPV16 infection and the relative risk ratios (RRRs) of 
HPV16 viral load levels using unconditional logistic regression and multinomial logistic 
regression, respectively. To specifically address the impact of loss of a family member on 
recurrent HPV infection, we stratified the analyses by the HPV16 status in the preceding 
smears. In addition, for smears tested for 32 HPV types, we derived the ORs of any positive 
as well as high-risk and low-risk HPV infections using unconditional logistic regression. All 
analyses were controlled for age at smear and within-subject correlation using robust variance 
estimates. 
Analyses of abnormal cytology 
We calculated the OR of the first abnormal cytology using conditional logistic regression. We 
further stratified the analysis by screening adherence. We divided the high and low screening 
adherence according to the median degree of participation among all screened women. 
Because abnormal cytologies require further workup, some may lead up to diagnosis of in 
situ or invasive cervical cancer. To address the concern of such driving force, in a sensitivity 
analysis, we excluded abnormal cytologies with a subsequent diagnosis of either in situ or 
invasive cervical cancer within the following six months. 
Analyses of in situ and invasive cervical cancer 
Similar to the analyses of abnormal cytology, we first derived the ORs of in situ and invasive 
cervical cancer from conditional logistic regression, and then stratified the analyses by 
screening adherence. Additionally, to evaluate the potential effect modification,(88,93) we 
stratified the analyses by age at the reference date, and plotted ORs using locally weighted 
scatter-plot smoothing.(151) 
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5.2 MENTAL DISORDERS, STRESSFUL LIFE EVENTS, AND CERVICAL 
CANCER SURVIVAL (PAPER II) 
Based on the national Cervical Cancer Audit, we included 4,269 women with cervical cancer 
and followed them from the date of cancer diagnosis until death, emigration, or December 
31st, 2013, whichever came first. Through the Causes of Death Register, we identified any 
death of the patients during the follow-up and the underlying cause. Information on 
demographic characteristics (including country of birth and highest educational level) and 
comorbidity in Charlson index(152) at the time of diagnosis was obtained through cross-
linkage to Swedish registers.  
The cancer-specific mortality was our primary outcome, while overall mortality was regarded 
as the secondary outcome. We defined the cancer-specific mortality if the death was recorded 
due to cervical cancer (ICD-10: C53) or unspecified uterine cancers (C55).(35) We assessed 
stress-related mental disorders and stressful life events as two separate indicators reflecting 
severe psychological distress experienced by women with cervical cancer. 
5.2.1 Stress-related mental disorders 
We used newly diagnosed mental disorders (i.e., close to cancer diagnosis and thereafter) as a 
proxy for the severe psychological distress experienced as a result of the diagnosis, treatment 
and progression of cervical cancer.(153) Several mental disorders were common among 
cancer patients and potentially related to psychological distress,(153-155) for instance stress 
reaction or adjustment disorders (ICD-10: F43), depression (F32-F33), and anxiety disorder 
(F40-F41). We therefore studied these three disorders, and defined the exposure as the first 
inpatient or outpatient visit for these disorders as the underlying reasons (i.e., the primary 
diagnosis) from one year before cancer diagnosis until the end of follow-up. A new diagnosis 
of such mental disorders was assured if no hospital visit regarding the same mental disorders 
was observed during the year preceding the defined diagnosis date of these mental disorders. 
5.2.2 Stressful life events 
Stressful life events are other common stress sources for cancer patients in addition to the 
malignant disease. We studied four life events that are both major and relatively 
common,(19) including loss or severe illness of a family member, divorce, and job loss. 
Because recent life events might better reflect the emotional burden,(156) we ascertained any 
first occurrence of these life events from one year before cancer diagnosis until the end of 
follow-up. Similar to the definition of newly diagnosed mental disorders, for the severe 
illness of a family member, we only included newly diagnosed illnesses in the family 
members.  
Using the same methods as in Study I, we identified the family members (i.e., parents, 
children, spouse, and siblings) of all women and ascertained any loss of a family member due 
to death. By linking all family members to the Patient and Cancer Registers, we also 
ascertained any severe illness of the family members which was defined a priori as illness 
with a disability weight over 0.40 in the Global Disease Burden 2004(157) and relatively 
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common in Sweden (Table 4). The change of marital status from “married” to “unmarried” in 
LISA was regarded as divorce. Job loss was assessed when one was registered as “actively 
seeking for a job” in LISA. Because patients may discontinue work on their own choice due 
to a poor health, we did not consider the recorded “no employment” alone as job loss.  
Table 4. Definition of severe illnesses of the family members, based on the disability 
weight in Global Disease Burden 2004.  
Disease ICD-10 Disability weight* 
First-ever stroke I61-I64 0.920 
Cretinism E00 0.804 
Severe depressive episodes F322, F323, F332, F333 0.760 
Metastatic and terminal cancer† C77-C79, or tumor stage as M1 0.75-0.81 
Injured spinal cord T093 0.725 
Alzheimer and other dementias F00-F03, F051, G30, G311 0.666 
Tetanus A33-A35 0.638 
Japanese encephalitis A830 0.616 
Bacterial meningitis G00, G03 0.615 
Poisoning X60-X69 0.608-0.611 
Dengue hemorrhagic fever A91 0.545 
Chronic obstructive pulmonary disease J44 0.530 
Schizophrenia F20-F29 0.528 
Burns 20%-60% T312-T316 0.441 
Burns >60% T317-T319 0.441 
Acute myocardial infarction (treated) I21, I22 0.439 
Fractured skull S02 0.431 
Rectovaginal fistula N823 0.430 
Multiple sclerosis G35 0.411 
 Reasons Disability weight* 
Excluded:   
Major congenital malformations Unlikely to be newly diagnosed for family members of cervical patients. 
0.593-
0.850 
Gonorrhea/Onchocerciasis/Trachoma – 
blindness 
Sequela of these infections is not identifiable in 
registers and they are extremely rare in Sweden.  
0.581-
0.600 
Chlamydia – ectopic pregnancy The ditto  0.549 
Tubo-ovarian abscess Unlikely to be “severe” in Sweden. 0.548 
AIDS not on ART (untreated) The universal coverage of healthcare in Sweden guarantees equal access, and untreated AIDS is rare.  0.505 
Malaria – neurological sequelae Sequela of this infection is not identifiable in registers and it is extremely rare in Sweden. 0.471 
Ascariasis – cognitive impairment The ditto  0.463 
Appendicitis Unlikely to be “severe” in Sweden. 0.463 
Meningitis – mental retardation Sequela of this infection is not identifiable in registers and it is extremely rare in Sweden.  0.459 
Pertussis –  encephalopathy The ditto  0.452 
* Disability weights represent the magnitude of health loss associated with the outcome on a scale from 0 to 1. 0 
implies a condition equivalent to full health, while 1 means a state equivalent to death.  
† In addition to the Patient Register, the Cancer Register was used to complement the diagnoses of metastatic or 
terminal cancer using the same ICD-10 codes and tumor stage as M1. The Cancer Register is virtually complete 
for newly-diagnosed malignancies, and information on tumor stage is largely available from 2004 onward. 
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5.2.3 Statistical analysis 
We treated the exposure to stress-related mental disorders and stressful life events in a time-
varying manner. Namely, women were defined as exposed from the date of cancer diagnosis 
onward if they encountered mental disorders or life events in the year preceding cancer 
diagnosis. For women who were exposed to mental disorder or life events after cancer 
diagnosis, they were first classified as unexposed and then exposed from the date of 
occurrence of the mental disorder or life event. Women were defined as unexposed 
throughout if they did not experience any mental disorders or life events from one year before 
cancer diagnosis until end of follow-up.  
We first compared differences of demographic and clinical characteristics between exposed 
and unexposed women using t test or chi-square test. We then estimated the hazard ratios 
(HRs) of overall mortality among exposed women, compared to unexposed women, from the 
Cox proportional hazards model. In this analysis, we adjusted for age at diagnosis, calendar 
year at diagnosis (2002-2004, 2005-2007, or 2008-2011), highest education level (primary 
school or unknown, high school, or college and beyond), country of birth (Nordic or non-
Nordic), and number of family members at diagnosis.  
For cancer-specific mortality, we examined the associations of mental disorders and life 
events collectively and individually. As the primary analysis, we first adjusted for the 
aforementioned covariates as a simple model; and we, in a full model, additionally controlled 
for FIGO stage (IA, IB, II, or ≥III), histology (squamous cell or others), mode of detection 
(due to screening or symptoms), primary treatment (operation, palliative care, or others), 
adjuvant therapy (yes or no), and Charlson comorbidity (yes or no). To understand the 
potentially different impact of characteristics of the life events, we further assessed 
bereavement by cause of death (i.e., natural or unnatural cause of death) and severity of the 
illness of a family member (i.e., the disability weights ≥0.5 or 0.4-0.5). 
To shed light on the temporal pattern, we estimated the HRs of cancer-specific mortality in 
different time windows after mental disorders or life events, i.e., within first six months, six 
months to <two years, or two years and beyond, since the exposure. The analysis during the 
first six months after exposure was to illustrate the potential reverse causality (i.e., mental 
disorders or life events were the consequences, rather than the causes, when one was dying of 
cancer). Provided with the potentially varying effect of psychological stress through the 
cancer continuum,(4,153) we also examined the risk of cancer-specific mortality by the 
timing of the occurrence of mental disorders and life events, i.e., from one year before to one 
year after cancer diagnosis and thereafter. 
5.3 STRESS-RELATED SIGNALING PATHWAYS AND LETHAL PROSTATE 
CANCER (PAPERS III & IV) 
Within the PHS and HPFS Prostate Tumor Tissue Cohort, we sampled 404 men using the 
extreme-case design. Namely, among men with sufficient usable tumor tissue, we included 
all men (N=113) who died of prostate cancer or developed distant metastases during follow-
 26 
up as lethal cases, and randomly sampled 291 men who lived eight years after cancer 
diagnosis and who neither developed metastases nor died of prostate cancer through 2012 as 
nonlethal cases. The archival formalin-fixed, paraffin embedded (FFPE) tumor specimens 
were retrieved for all included men. 404 tumor tissues and 202 normal adjacent tissues 
(whenever available) were profiled for the gene expression.  
Within the Swedish Watchful Waiting Cohort, using the same design, we first sampled 262 
men to profile the gene expression in tumor tissue; and, in a second sampling, we included 
396 men to genotype candidate SNPs in adjacent normal tissue. For the analysis of gene 
expression, we included 141 men who died of prostate cancer during follow-up as lethal 
cases and 121 men who lived seven years after cancer diagnosis as nonlethal cases, among 
men with high-quality tumor tissue. For the analysis of genetic variants, we enrolled 126 
lethal and 270 nonlethal cases from men with available normal tissue. Altogether, 186 lethal 
and 325 nonlethal cases were included from the Swedish data. 
We carried out the analysis of gene expression in stress-related pathways for both of the US 
and Swedish data, and additionally performed the analysis of candidate SNPs in these 
pathways in the Swedish data. We examined the lethal cancer as the primary outcome, and 
assessed the biomarkers and histopathological characteristics as the secondary outcomes. 
5.3.1 Candidate genes in the stress-related pathway 
We studied four stress-related pathways with a confirmed link to psychological stress, namely 
the adrenergic, glucocorticoid, serotoninergic, and dopaminergic pathways. We used the 
Kyoto Encyclopedia of Genes and Genomes (KEGG), Pathway Maps (Thomson Reuters) 
and previous literature to identify the candidate genes in each pathway. To concentrate on the 
tumor-specific impact, we excluded genes in the branches of signaling cascade leading to 
cardiovascular and neuronal functions from the adrenergic signaling pathway. In total, 234 
genes from the studied four pathways were included for the analysis of gene expression. Of 
note, an individual gene could contribute to multiple pathways. 
To conservatively assess the independent effect of the pathway without crosstalk, for the US 
data, the analysis was further restricted to the 46 exclusive genes prior to all data analyses. 
The exclusive genes were defined as the upstream genes preceding to any common signaling 
transduction among four pathways. The majority is therefore the receptor genes except for the 
glucocorticoid pathway. Regarding the Swedish data, 234 genes whenever available (N=163) 
were used for the analysis of gene expression. In an alternative approach, we restricted the 
analysis to 116 specific genes which are only present in one pathway, in order to control for 
the crosstalk between pathways as much as possible. 
5.3.2 RNA extraction, profiling and data preprocessing 
For the US samples, we first extracted RNA from the tumor and adjacent normal tissues on 
the Biomek FxP automated platform using the Agencourt FormaPure FFPE kit (Beckman), 
and then amplified it using the WT-Ovation FFPE System V2 (Nugen). After the whole 
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transcriptome amplification, the cDNA was hybridized to the GeneChip Human Exon 1.0 ST 
microarray (Affymetrics), which profiles expression of >28,000 genes with an average of 26 
probes per gene. We have conducted a pilot study to validate the gene expression 
quantification from FFPE tissues on this platform (158). The Affymetrix data was normalized 
using the Robust Multi-array Average method according to samples and batches,(159) and 
was mapped to 20,254 unique named genes using the NetAffx annotations. The expression 
data have been submitted to the Gene Expression Omnibus (accession number: GSE62872). 
For the Swedish samples, we extracted RNA from the tumor tissue in a 96-well format using 
the CyBi-Well liquid handling system (CyBio AG), and quantified it using the NanoDrop 
spectrophotometer (NanoDrop Technologies). Using the four cDNA-mediated annealing, 
selection, ligation, and extension (DASL) assay panels, we then profiled the expression data 
of 6100 genes.(160) The expression data were normalized by using a cubic spline algorithm 
and submitted to the GEO (accession number: GSE16560). 
5.3.3 Genotyping 
For the Swedish samples (396 men with normal tissue available), we additionally genotyped 
36 SNPs across the main receptor genes (N=14) in the four pathways. The set of SNPs were 
selected based on previous literature suggesting a link to prostate or other cancers. We 
extracted the DNA from normal tissue using the Sequenom iPLEX platform assay at the 
Genotyping Core Facility at Children's Hospital, Boston.(161) After excluding SNPs with a 
call rate <95% (N=4), with a minor allele frequency <5% (N=1), and with significant 
deviation from Hardy-Weinberg equilibrium (N=1), 30 SNPs were included for the analysis. 
We also excluded eight men due to low genotyping quality of the sample (genotyped <85% 
working SNPs).  
5.3.4 Biomarkers and histopathological characteristics 
We assessed the biomarkers and histopathological characteristics for both US and Swedish 
data unless indicated. The total sample size varied by biomarkers and histopathological 
characteristics due to data availability. 
Cell proliferation 
We measured the expression of Ki-67 on 4 or 5 µm sections of tumor tissue to assess the cell 
proliferation, using the rabbit polyclonal antibody (Vector Labs).(162,163)  After 
immunohistochemical staining, we quantified the percentage of Ki-67 positive nuclei among 
all tumor nuclei using the Ariol instrument SL-50 (Applied Imaging). 
Apoptosis 
We used the TUNEL assay on 4 or 5 µm sections of tumor tissue to estimate the proportion 
of tumor cells undergoing apoptosis. The Apoptag Peroxidase In situ kit (Chemicon 
International) was used for staining, and the percentage of positively-stained cells over all 
tumor cells was calculated.(162,164) 
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Angiogenesis 
The angiogenesis was only assessed in the HPFS in the US sample based on the protein 
expression of endothelial cell marker CD34. After staining by the anti-CD34 mouse 
monoclonal antibody (QBEnd-10) and peroxidase blocking reagent (Dual Endogenous 
Enzyme Block, DakoCytomation), semi-automated image analysis (Image ProPlus 4.5 
software, Media Cybernetics) was used to quantify the size and architecture.(70) Microvessel 
density was defined as the number of vascular structures per one high-powered field. Vessel 
size was calculated as the mean vessel diameter (µm), and area occupied by a vessel (µm2). 
TMPRSS2–ERG fusion 
In the Swedish sample, we assessed the ERG rearrangement status by using an ERG break-
apart fluorescence in situ hybridization (FISH) assay.(165) In cases not assessed by FISH, 
qPCR was performed in a portion of the RNA extraction used for DASL.(75) Relative 
quantification was preformed using the 2−ΔΔCT method.(166) 
Other biomarkers and histopathological characteristics 
Gleason score was re-reviewed through hematoxylin and eosin slides for all patients. 
Prostate-specific antigen (PSA) levels at diagnosis and tumor stage were obtained from the 
medical records and pathology reports in the US data, whereas tumor stage was re-reviewed 
in the slides in the Swedish data. Presence of perineural invasion was also assessed in the 
slides. Prostatic intraepithelial neoplasia (PIN) was only reviewed in adjacent areas in the 
Swedish samples. 
5.3.5 Statistical analysis 
Pathway analysis 
In both the US and Swedish samples, we examined the overall associations of differential 
gene expression in four candidate pathways with the risk of lethal prostate cancer as the 
primary outcome, as well as with biomarkers and histopathological characteristics as the 
secondary outcomes. In the US sample, we performed the likelihood ratio test on the logistic 
regression model to compare the null model (controlled for age at diagnosis and cohort 
membership) with the full model (additionally including the genes in the candidate pathway), 
because of small pathway sizes (6-17 exclusive genes). Regarding the Swedish sample, we 
assessed the associations using the global test, in order to handle larger and different sizes of 
gene sets(167), and adjusted for age at diagnosis. Because we aimed to describe the potential 
difference in signaling of these pathways, instead of developing prediction models, we did 
not adjust for Gleason score or tumor stage in our primary model; we however controlled for 
and performed subgroup analyses by these variables for both samples in the secondary model.  
We conducted different sensitivity analyses for both samples. For the US sample, we carried 
out the Gene Set Enrichment Analysis (GSEA) (168) to assess the importance of the 
candidate pathways relative to other unrelated genes in terms of the lethal cancer. GSEA is a 
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competitive pathway test comparing the differential expressions of the genes in the working 
pathway with differential expression of other genes. This test does not control for clinical 
covariates, in order to calculate P-values based on permuting individuals in the study. It does, 
however, provide a direction for the association, namely whether up-regulation or down-
regulation of the gene expression is associated with the lethal cancer. In the Swedish sample, 
we restricted the pathway analysis to 116 specific genes which were not shared with other 
candidate pathways, to reduce the crosstalk between candidate pathways. 
To understand if the differential signaling of the candidate pathways pertains in the tumor 
tissue, we also assessed the associations in the adjacent normal prostate tissue in the US 
sample.  
To shed light on the potential biological mechanisms for the noted associations, we further 
examined the relationships of the candidate pathways with biomarkers and histopathological 
characteristics for both samples. In the US samples, we classified all outcomes into 
categorical variables and assessed the pathway significance using likelihood ratio tests on 
logistic regression (if binary outcome) or proportional odds models. For the Swedish samples, 
all histopathologic characteristics were used as binary outcomes and all quantitative 
biomarkers were used as continuous outcomes, examined in the global test. 
SNP analysis 
We only performed the SNP analysis for the Swedish sample. Using logistic regression 
model with no further adjustment, we examined the associations of candidate SNPs with the 
risk of lethal prostate cancer. We first explored different effect models, including additive, 
recessive, dominant, and over-dominant models; and then estimated the ORs based on the 
most significant effect model. To shed light on the underlying mechanisms, we also 
examined the associations with the biomarkers and histopathological characteristics for the 
significant SNPs found for lethal cancer, using the same effect model. 
To further understand the impact of genetic variation on the pathway signaling, we performed 
the Quantitative Trait Loci (eQTL) analysis using linear regression model(169) to assess the 
correlation between significant SNPs noted above and the expression of genes in the same 
pathway. For this analysis, we adjusted for age at diagnosis, calendar period at diagnosis, 
Gleason score, tumor stage, and lethal cancer in the subgroup of men that were both profiled 
for gene expression and genotypes (N=154; 82 lethal and 72 nonlethal cases). 
Since we were examining four independent pathways, we considered a P value <0.0125 to 
indicate a statistical significance in the pathway analyses of both samples, as correction for 
multiple testing.(170) As we took a pathway-based approach to test specific a priori 
hypotheses, we did not further control for multiple testing in the subsequent analyses of SNPs 
in the Swedish sample.   
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5.4 ETHICAL CONSIDERATIONS 
Papers I & II are largely based on public and health registers in Sweden. Both studies were 
approved by the Regional Ethical Review Board in Stockholm (EPN 2012/1783-32, 
2011/1547-32, and 2015/719-32), and the requirement of informed consent from participants 
was waived. Data linkage was carried out by the Statistics Sweden and the National Board of 
Health and Welfare, and the personal identity number was replaced by a study identification 
number. The host institute secures the data through strict safety guidelines and limited access. 
Paper III, including prostate cancer patients from the PHS and the HPFS in the US, was 
approved by the institutional review boards at the Harvard School of Public Health and 
Partners Health Care (2009P001231/BWH). Written informed consent was obtained from 
each participant. The Swedish Watchful Waiting Cohort was originally approved by the 
Regional Ethical Review Board in Linköping (EPN M58-05), who also decided to waive the 
requirement of informed consent forms from included patients. Based on this cohort, Paper 
IV was approved by the Regional Ethical Review Board in Uppsala (EPN 2012/361). Both 
studies assessed mRNAs, and Paper IV additionally SNPs, using the specimens collected 
from surgical treatment. Although most peer-reviewed journals require the submission of 
microarray data to public repositories, the personal information is anonymized and the odds 
for inappropriate spread of such information are minimal. 
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6 RESULTS 
6.1 BEREAVEMENT, HPV INFECTION, AND CERVICAL CARCINOGENESIS 
(PAPER I) 
HPV Infection 
Compared to women without loss, loss of a family member was positively associated with 
HPV16 infection (Table 5). The association was stronger among women with a history of 
HPV16 infection (P<0.0001), and the risk elevation tended to be greater among women with 
high screening adherence (P=0.060). Moreover, stronger and significant association was 
noted for high viral load infection of HPV16 (RRR 2.84, 95% CI 1.29 to 6.29), rather than 
low viral load infection (RRR 0.73, 95% CI 0.73 to 2.44). The positive association of loss 
was further extended to infection of any HPV types tested (Table 5). The stronger and 
significant association was noted for infection of high-risk HPV types (OR 1.55, 95% CI 1.01 
to 2.37) rather than infection of low-risk types (OR 1.13, 95% CI 0.51 to 2.51).  
Table 5. Odds ratios (ORs) of HPV infection after bereavement. 
 Negative smear N(%) Positive smear N(%) OR (95% CI)* 
HPV16 infection    
No bereavement 3,038 (79.3) 158 (77.8) 1.0 
Bereavement 792 (20.7) 45 (22.2) 1.62 (1.05-2.50) 
Stratified by previous HPV16 infection 
  No     
    No bereavement 2,862 (79.7) 139 (81.3) 1.0 
    Bereavement 731 (20.4) 32 (18.7) 1.31 (0.86-2.00) 
  Yes    
    No bereavement 176 (74.3) 19 (59.4) 1.0 
    Bereavement 61 (25.7) 13 (40.6) 3.94 (1.24-12.48) 
  P for difference†   <0.0001 
Stratified by screening adherence 
  High    
    No bereavement 2,039 (81.3) 90 (75.0) 1.0 
    Bereavement 468 (18.7) 30 (25.0) 1.95 (1.13- 3.38) 
  Low/unscreened    
    No bereavement 999 (75.5) 68 (81.9) 1.0 
    Bereavement 324 (24.5) 15 (18.1) 1.15 (0.58-2.28) 
  P for difference†   0.060 
    
Any HPV§    
No bereavement 1,426 (80.6) 230 (83.3) 1.0 
Bereavement 344 (19.4) 46 (16.7) 1.54 (1.03-2.30) 
* CI, confidence interval. ORs were estimated using unconditional logistic regression, and were controlled for 
age at smear and within-subject variance. 
† The P values for the interaction terms between bereavement and the stratification factors. 
§ Low-risk HPV includes types 6, 7, 11, 42, 43, and 70. High-risk HPV includes types 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 66, 68, 73, and 82. 
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Abnormal Cytology 
Loss of a family member was associated with a slightly but significantly increased risk of 
abnormal cytology (OR 1.04, 95% CI 1.03 to 1.05; Table 6). Such associations were 
consistently observed for atypical (OR 1.04, 95% CI 1.02 to 1.05), low-grade (OR 1.03, 95% 
CI 1.02 to 1.05), and high-grade abnormality (OR 1.04, 95% CI 1.02 to 1.06). Of note, the 
dose-response effect, i.e. number of losses, on abnormal cytology was evident (P<0.0001; 
Table 6). Moreover, the ORs were significantly greater for loss of a child, spouse, or sibling, 
loss due to unnatural cause of death, and among women with higher screening adherence. 
The association, however, was not modified by time since loss. The association of loss with 
the risk of abnormal cytology hardly changed after excluding abnormal cytologies leading to 
cervical cancer diagnosis in six months (OR 1.03, 95% CI 1.02 to 1.04).  
Table 6. Odds ratios (ORs) of abnormal cytology after bereavement. 
 Normal cytology N(%) Abnormal cytology N(%) OR (95% CI)* 
No bereavement 1,389,548 (71.2) 275,830 (70.7) 1.0 
Bereavement 561,771 (28.8) 114,480 (29.3) 1.04 (1.03-1.05) 
  Number of bereavements    
    1  401,738 (20.6) 81,260 (20.8) 1.03 (1.02-1.04) 
    2 136,626 (7.0) 27,844 (7.1) 1.05 (1.04-1.07) 
    3 20,418 (1.1) 4,578 (1.2) 1.17 (1.13-1.21) 
    ≥4 2,989 (0.2) 798 (0.2) 1.40 (1.29-1.52) 
    P for trend†   <0.0001 
  Type of bereavement    
    Loss of a parent 474,561 (24.3) 95,323 (24.4) 1.02 (1.01-1.03) 
    Loss of a child, spouse, or sibling 87,210 (4.5) 19,157 (4.9) 1.12 (1.10-1.14) 
    P for difference§   <0.0001 
  Cause of bereavement    
    Unnatural cause 66,224 (3.4) 14,602 (3.7) 1.12 (1.09-1.14) 
    Natural cause 495,547 (25.4) 99,878 (25.6) 1.02 (1.01-1.03) 
    P for difference§   <0.0001 
  Time since bereavement    
    ≤1 year 97,087 (5.0) 19,797 (5.1) 1.04 (1.02-1.05) 
    2-4 years 118,769 (6.1) 24,546 (6.3) 1.05 (1.04-1.07) 
    ≥5 years 345,915 (17.7) 70,137 (18.0) 1.03 (1.02-1.04) 
Stratified by screening adherence    
  High    
No bereavement 588,071 (76.6) 116,343 (75.8) 1.0 
Bereavement 179,499 (23.4) 37,173 (24.2) 1.06 (1.04-1.07) 
  Low    
No bereavement 428,556 (58.1) 85,016 (57.6) 1.0 
Bereavement 309,433 (41.9) 62,593 (42.4) 1.03 (1.01-1.04) 
  Unscreened    
    No bereavement 372,921 (83.7) 74,471 (83.5) 1.0 
Bereavement 72,839 (16.3) 14,714 (16.5) 1.02 (0.99-1.04) 
  P for difference‡   0.002 
* CI, confidence interval. Birth year and screening adherence were matched on and therefore inherently adjusted 
for in all models. 
† Cochran-Armitage test. 
§ Wald test.  
‡ The P value for the interaction terms between bereavement and screening adherence. 
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Cervical Cancer 
We observed mildly increased risk of in situ or invasive cervical cancer after loss of a family 
member (Table 7). Excess risk was also noted for in situ (OR 1.07, 95% CI 1.04 to 1.09) and 
invasive cancer (OR 1.09, 95% CI 1.02 to 1.17), respectively. The associations of in situ or 
invasive cancer were more pronounced for multiple losses, loss of a child, spouse, or sibling, 
loss due to unnatural cause of death, and among women with higher screening adherence 
(Table 7). The risk elevations, however, did not differ by time since loss. Women with loss of 
a child, spouse or sibling were consistently at higher risk of in situ cervical cancer throughout 
different age bands, whereas loss of a parent was only related to a mildly increased risk in 
younger ages (Figure 2). Similar patterns were noted for the risk of invasive cervical cancer. 
 
Table 7. Odds ratios (ORs) of in situ or invasive cervical cancer after bereavement. 
 No cervical cancer N(%) Cervical cancer N(%) OR (95% CI)* 
No bereavement 267,919 (71.3) 52,797 (70.3) 1.0 
Bereavement 107,721 (28.7) 22,331 (29.7) 1.07 (1.05-1.09) 
  Number of bereavements 
    1  80,052 (21.3) 16,414 (21.9) 1.06 (1.03-1.08) 
    2 23,558 (6.3) 4,868 (6.5) 1.09 (1.05-1.13) 
    3 3,439 (0.9) 878 (1.2) 1.37 (1.27-1.49) 
    ≥4 672 (0.2) 171 (0.2) 1.40 (1.18-1.66) 
    P for trend†   <0.0001 
  Type of bereavement    
    Loss of a parent 90,068 (24.0) 18,203 (24.2) 1.04 (1.02-1.06) 
    Loss of a child, spouse, or sibling 17,653 (4.7) 4,128 (5.5) 1.20 (1.16-1.25) 
    P for difference§   <0.0001 
  Cause of bereavement    
    Unnatural cause 13,997 (3.7) 3,254 (4.3) 1.19 (1.14-1.23) 
    Natural cause 93,724 (25.0) 19,077 (25.4) 1.05 (1.02-1.07) 
    P for difference§   <0.0001 
  Time since bereavement    
    ≤1 year 18,145 (4.8) 3,728 (5.0) 1.06 (1.02-1.10) 
    2-4 years 22,629 (6.0) 4,710 (6.3) 1.07 (1.04-1.11) 
    ≥5 years 66,947 (17.8) 13,893 (18.5) 1.07 (1.05-1.09) 
Stratified by screening adherence 
  High    
No bereavement 109,281 (77.5) 21,425 (76.0) 1.0 
Bereavement 31,769 (22.5) 6,785 (24.1) 1.11 (1.07-1.14) 
  Low    
No bereavement 96,282 (62.1) 19,037 (61.4) 1.0 
Bereavement 58,763 (37.9) 11,972 (38.6) 1.04 (1.01-1.07) 
  Unscreened    
    No bereavement 62,356 (78.4) 12,335 (77.5) 1.0 
Bereavement 17,189 (21.6) 3,574 (22.5) 1.07 (1.02-1.12) 
  P for difference‡   0.018 
* CI, confidence interval. Birth year and screening adherence were matched on and therefore inherently adjusted 
for in all models. 
† Cochran-Armitage test. 
§ Wald test.  
‡ The P value for the interaction terms between bereavement and screening adherence. 
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Figure 2. Odds ratios (ORs) of in situ and invasive cervical cancer after bereavement, 
by age at diagnosis. We performed the subgroup analyses on in situ cervical cancer by ≤25 years, every 5 
years thereafter, and ≥61 years and analyses on invasive cervical cancers by ≤30 years, every 10 years 
thereafter, and ≥71 years. We plotted the scatters of odds ratios (ORs) and confidence intervals at the median 
age of each age group, as well as lines of smoothed ORs which were derived from locally weighted scatterplot 
smoothing. 
 
Lifestyle Factors 
Women with loss of a family member were older at the time of the interview and, if ever 
smoking, had started smoking at a younger age (Table 8). However, loss was not related to 
self-reported smoking status, use of oral contraceptives, sexual behaviors, parity, or number 
of abortions (P >0.05). 
 
 
  35 
 
Table 8. Distribution of lifestyle factors between women with and without bereavement* 
Characteristics No bereavement Bereavement P for difference† 
Number 155 190 - 
Age at interview 42 (26-63) 49 (29-63) <0.0001 
Age at bereavement - 42 (9-57) - 
Smoking    
    Ever smoker‡ 90 (58.1) 107 (56.3) 0.741 
    Current smoker 37 (23.9) 52 (27.4) 0.460 
    Age at smoking debut 16 (12-35) 17 (12-37) 0.013 
Oral contraceptive use§    
    Ever user 130 (84.4) 154 (81.1) 0.414 
    Current user 19 (12.3) 12 (6.3) 0.055 
Sexual behavior    
    Age at sexual debut 17 (12-30) 17 (11-30) 0.520 
    No. of sexual partners    
      Maximum  5 (1-53) 4 (1-35) 0.236 
      At age 20-25  2 (0-42) 2 (0-15) 0.921 
Parity 2 (0-6) 2 (0-6) 0.086 
Number of abortions 0 (0-4) 0 (0-2) 0.978 
* Among 345 women included for this analysis, one woman had missing data on use of oral contraceptive; two 
women had missing data on age at sexual debut; and four women had missing data on number of sexual partners. 
Number (percentage) or median (range) was presented. 
† Chi-square test was used to test the different distributions by categorical variables (smoking and oral 
contraceptive use); and Mann–Whitney U test for continuous variables (age at interview, age at smoking debut, 
age at sexual debut, number of sexual partners, parity and abortion). 
‡ Ever smoker was defined as women who smoked at least six months.  
§ Combined estrogen-progestin compounds only. 
 
6.2 MENTAL DISORDERS, STRESSFUL LIFE EVENTS, AND CERVICAL 
CANCER SURVIVAL (PAPER II) 
We identified 1,839 (43%) patients with cervical cancer that experienced a stress-related 
mental disorder or stressful life event from the year before cancer diagnosis until end of 
follow-up (Table 9). 388 (21.1%) patients encountered a mental disorder, while 1,634 (88.9) 
patients had a life event. Compared to the unexposed patients, the exposed patients were 
younger at diagnosis, and were more likely diagnosed in earlier calendar years and free of 
comorbidities at diagnosis. Their cancers were also more likely below stage III, from 
squamous cell origin, detected by screening, and treated surgically. 
In the average follow-up of 4.3 years, 1,396 (32.7%) patients died and 1,009 (72.3%) of these 
had cervical cancer-specific death. Patients with either a mental disorder or stressful life event 
from one year before cancer diagnosis onward had a significantly increased risk of overall 
mortality (HR 1.23, 95% CI 1.08 to 1.40), irrespective of age, calendar year, family size at 
diagnosis, education level, or country of birth, compared to the unexposed patients.  
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Table 9. Demographic and clinical characteristics between cervical cancer patients with 
and without exposure to any stress-related mental disorders or stressful life event.  
 Patients without exposure N(%) or mean ± SD 
Patients with exposure 
N(%) or mean ± SD 
P for 
difference 
Total number 2,430 1,839  
Age at diagnosis, years 56.7±19.4 50.2±15.4 <0.001 
Calendar year at diagnosis   <0.001 
  2002-2004 638 (26.3) 645 (35.1)  
  2005-2007 674 (27.7) 605 (32.9)  
  2008-2011 1,118 (46.0) 589 (32.0)  
FIGO stage   <0.001 
  IA 448 (18.4) 421 (22.9)  
  IB 875 (36.0) 816 (44.4)  
  II 470 (19.3) 348 (18.9)  
  III+ 637 (26.2) 254 (13.8)  
Histology   0.047 
  Unknown 2 (0.1) 0 (0.0)  
  Squamous cell cancer 1,721 (70.8) 1,334 (72.5)  
  Adenocarcinoma 527 (21.7) 391 (21.3)  
  Adenosquamous cell cancer 82 (3.4) 68 (3.7)  
  Others 98 (4.0) 46 (2.5)  
Mode of detection   <0.001 
  Screening 626 (25.8) 624 (33.9)  
  Symptom 1,804 (74.2) 1,215 (66.1)  
Operation   <0.001 
  No 1,232 (50.7) 629 (34.2)  
  Conization 180 (7.4) 150 (8.2)  
  Trachelectomy 56 (2.3) 36 (2.0)  
  Hysterectomy 179 (7.4) 179 (9.7)  
  Radical hysterectomy 783 (32.2) 845 (45.9)  
Chemotherapy   0.476 
  No 1,670 (68.7) 1,245 (67.7)  
  Yes 760 (31.3) 594 (32.3)  
Radiation therapy   0.090 
  No 1,160 (47.7) 926 (50.4)  
  Yes 1,270 (52.3) 913 (49.6)  
Palliative care   <0.001 
  No 2,153 (88.6) 1,788 (97.2)  
  Yes 277 (11.4) 51 (2.8)  
Comorbidity at diagnosis   <0.001 
  No 1,700 (70.0) 1,404 (76.3)  
  Yes 730 (30.0) 435 (23.7)  
FIGO, International Federation of Gynecology and Obstetrics; SD, standard deviation. 
 
Exposure to a stress-related mental disorder or a stressful life event was associated with a 
31% increased risk of cancer-specific mortality (95% CI 1.13 to 1.52; Table 10). After 
additional adjustment for multiple clinical characteristics, the association became slightly 
weaker but remained statistically significant (HR 1.25, 95% CI 1.07 to 1.44). Although some 
results were not statistically significant, an increased risk of cancer-specific mortality was 
found for all individual mental disorders and life events. Of note, the association of loss of a 
family member due to unnatural causes of death tended to be stronger, compared to loss due 
to natural causes. A similar pattern was observed for having a family member with more 
severe illness (i.e., of disability weight ≥0.5), compared to having a family member with less 
severe illness. 
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Table 10. Hazard ratios (HRs) of cancer-specific mortality after stress-related mental 
disorders or stressful life events. 
 N (IR) HR (95% CI)* HR (95% CI)† 
Reference 733 (62.0) 1.0 1.0 
Stress-related mental disorders or 
stressful life events 276 (39.8) 1.31 (1.13-1.52) 1.25 (1.07-1.44) 
By individual disorders or events    
Mental disorders 69 (52.3) 1.83 (1.42-2.35) 1.55 (1.21-2.00) 
  Stress reaction or adjustment disorder 15 (44.5) 1.80 (1.08-3.02) 1.79 (1.07-2.99) 
  Depression 27 (47.1) 1.60 (1.08-2.35) 1.21 (0.82-1.78) 
  Anxiety 27 (66.1) 2.16 (1.46-3.18) 1.97 (1.34-2.91) 
Life events 226 (36.5) 1.22 (1.04-1.43) 1.19 (1.02-1.40) 
  Loss of a family member 104 (39.7) 1.23 (0.99-1.53) 1.23 (0.99-1.53) 
Due to natural cause 98 (39.2) 1.23 (0.99-1.53) 1.23 (0.98-1.53) 
    Due to unnatural cause 10 (54.0) 1.56 (0.83-2.92) 1.81 (0.96-3.41) 
  Severe illness of a family member 136 (38.8) 1.29 (1.06-1.56) 1.19 (0.98-1.45) 
    Disability weight ≥0.5 97 (39.3) 1.37 (1.10-1.71) 1.24 (1.00-1.55) 
    Disability weight 0.4-0.5 44 (34.5) 1.13 (0.83-1.54) 1.07 (0.78-1.46) 
  Divorce 35 (36.5) 1.21 (0.86-1.70) 1.08 (0.77-1.52) 
  Job loss 22 (20.2) 1.35 (0.88-2.09) 1.40 (0.90-2.16) 
CI, confidence interval; HR, hazard ratio; IR, incidence rate, per 1,000 person-years.  
* HRs were adjusted for age at diagnosis, calendar year at diagnosis (2002-2004, 2005-2007, or 2008-2011), 
education level (primary school or unknown, high school, or college+), country of birth (Nordic or non-Nordic), 
and family size at diagnosis. 
† HRs were additionally adjusted for FIGO stage (IA, IB, II, or III+), histology (squamous cell cancer or others), 
mode of detection (screening or symptom), primary treatment (operation, palliative care, or others), adjuvant 
therapy (yes or no), and Charlson comorbidity (yes or no). 
Significantly increased risks of cancer-specific mortality were noted both within six months 
and ≥2 years after exposure to a mental disorder (Table 11). By contrast, the significant 
association with cancer-specific mortality was only noted ≥2 years after exposure to a 
stressful life event. 
Table 11. Hazard ratios (HRs) of cancer-specific mortality after stress-related mental 
disorders or stressful life events, by time since exposure. 
 N (IR) HR (95% CI)* HR (95% CI)† 
Mental disorders    
  0 to <6 months  23 (143.2) 2.53 (1.67-3.85) 2.13 (1.40-3.23) 
  6 months to <2 years 28 (64.1) 1.51 (1.03-2.22) 1.24 (0.85-1.82) 
  ≥2 years 18 (25.0) 1.77 (1.09-2.88) 1.62 (1.00-2.64) 
Life events    
  0 to <6 months  30 (48.5) 0.94 (0.65-1.35) 0.89 (0.61-1.28) 
  6 months to <2 years 109 (57.1) 1.23 (1.00-1.52) 1.17 (0.96-1.45) 
  ≥2 years 87 (23.8) 1.42 (1.10-1.83) 1.42 (1.10-1.83) 
CI, confidence interval; HR, hazard ratio; IR, incidence rate, per 1,000 person-years.  
* HRs were adjusted for age at diagnosis, calendar year at diagnosis (2002-2004, 2005-2007, or 2008-2011), 
education level (primary school or unknown, high school, or college+), country of birth (Nordic or non-Nordic), 
and family size at diagnosis. 
† HRs were additionally adjusted family size at diagnosis, FIGO stage (IA, IB, II, or III+), histology (squamous 
cell cancer or others), mode of detection (screening or symptom), primary treatment (operation, palliative care, 
or others), adjuvant therapy (yes or no), and Charlson comorbidity (yes or no). 
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The excess risk of cancer-specific mortality was greater for stress-related mental disorders 
occurring more than one year after cancer diagnosis, compared to mental disorders occurring 
during the year before or the year after cancer diagnosis (Table 12). By contrast, significant 
associations with cancer-specific mortality were only noted for stressful life events that took 
place from one year before to one year after cancer diagnosis. 
Table 12. Hazard ratios (HRs) of cancer-specific mortality after stress-related mental 
disorders or stressful life events, by timing of the occurrence of such mental disorders 
or life events. 
 N (IR) HR (95% CI)* HR (95% CI)† 
Mental disorders    
  1 year before or after diagnosis 48 (62.8) 1.59 (1.19-2.14) 1.37 (1.02-1.84) 
  >1 year after diagnosis 21 (37.9) 2.68 (1.72-4.18) 2.38 (1.52-3.73) 
Life events    
  1 year before or after diagnosis 175 (54.7) 1.31 (1.10-1.55) 1.28 (1.08-1.52) 
  >1 year after diagnosis 51 (17.1) 0.96 (0.71-1.30) 0.93 (0.68-1.26) 
CI, confidence interval; HR, hazard ratio; IR, incidence rate, per 1,000 person-years.  
* HRs were adjusted for age at diagnosis, calendar year at diagnosis (2002-2004, 2005-2007, or 2008-2011), 
education level (primary school or unknown, high school, or college+), country of birth (Nordic or non-Nordic), 
and family size at diagnosis. 
† HRs were additionally adjusted for FIGO stage (IA, IB, II, or III+), histology (squamous cell cancer or others), 
mode of detection (screening or symptom), primary treatment (operation, palliative care, or others), adjuvant 
therapy (yes or no), and Charlson comorbidity (yes or no). 
6.3 STRESS-RELATED SIGNALING PATHWAYS AND LETHAL PROSTATE 
CANCER IN US MEN (PAPER III) 
In the US sample, we included tumor issue from 150 men in PHS and 254 men in HPFS 
(Table 13). Men from HPFS were more likely to have a Gleason score≥7, and therefore had 
more lethal cases. Normal tissue was available from 202 of these men. 
We found that differential expression of genes in the adrenergic, glucocorticoid, and 
serotoninergic pathways in prostate tumor tissue was significantly associated with the risk of 
lethal cancer (Table 14). The associations remained statistically significant for the 
glucocorticoid and serotoninergic pathways after adjusting for Gleason score and tumor 
stage. The association of differential signaling of the glucocorticoid pathway was also 
significant in tumors of both lower and higher stages, as well as in tumors of Gleason scores 
between 8 and 10. In the competitive pathway test (GSEA), we observed that the differential 
expression of genes in the adrenergic pathway was significant in relation to the risk of lethal 
cancer (P=0.001), compared to the differential expression of other unrelated genes. The 
adrenergic pathway tended to be down-regulated in the tumor tissue of lethal cancers. Of 
note, no pathway was differentially expressed in the adjacent normal tissue of the lethal 
cancers as compared to the nonlethal ones. 
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Table 13. Clinical characteristics of men with prostate cancer in Paper III. 
 PHS HPFS 
Total number 150 254 
With normal tissue, N(%) 82 (54.7) 120 (47.2) 
Calendar year of diagnosis, range 1982-2005 1986-2004 
Age at diagnosis (years), mean±SD 66±6.5 65±6.4 
Lethal cases, N(%) 30 (20.0) 83 (32.7) 
Gleason score, N(%)   
  5-6 33 (22.0) 24 (9.4) 
  7 (3+4) 48 (32.0) 91 (35.8) 
  7 (4+3) 28 (18.7) 74 (29.1) 
  8-10 41 (27.3) 65 (25.6) 
Tumor stage, N(%)*   
  T1/T2, N0/Nx 89 (59.3) 150 (59.1) 
  T3, N0/Nx 49 (32.7) 83 (32.7) 
  T4, N1, M1 12 (8.0) 21 (8.3) 
PSA at diagnosis, N (%)   
  0-3.9 ng/ml 15 (10.0) 18 (7.1) 
  4-9.9 ng/ml 79 (52.7) 119 (46.9) 
  10+ ng/ml 35 (23.3) 75 (29.5) 
  Unknown 21 (14.0) 42 (16.5) 
Physician’s Health Study (PHS) and Health Professional Follow-up Study (HPFS) 
* In the PHS, 18 men were missing pathological stage but had information on clinical stage, and therefore we 
used this information as an approximation for tumor stage: 12 were T1 or T2, 1 was T3, and 5 were T4 or N1 or 
M1.  In this HPFS, 17 men were missing this information, and we used their clinical stage: 9 were T1 or T2, 1 
was T3, 7 were T4 or N1 or M1. 
 
Table 14. P-values of pathways analyses in terms of risk of lethal prostate cancer in the 
PHS and HPFS Prostate Tumor Tissue Cohort.  
 N Adrenergic pathway 
Glucocorticoid 
pathway 
Serotoninergic 
pathway 
Dopaminergic 
pathway 
Number of genes  11 12 17 6 
In tumor tissue      
Primary model* 404 0.0010 <0.0001 0.0019 0.053 
Adjusting for Gleason 404 0.058 0.0012 0.013 0.39 
Adjusting for Gleason and 
stage 404 0.043 0.0006 0.0062 0.31 
Stratified by Gleason†      
  Gleason 7 241 0.063 0.098 0.017 0.51 
  Gleason 8-10 106 0.39 0.0002 0.062 0.16 
Stratified by stage      
  T1/T2, N0/Nx 239 0.071 <0.0001 0.13 0.12 
  T3/T4, N1, M1 165 0.034 0.0004 0.088 0.31 
GSEA test‡ 404 0.001 (↓) 0.31 (↑) 0.58 (↑) 0.47 (↓) 
In normal tissue      
Primary model* 202 0.31 0.29 0.37 0.58 
* In the primary model, we performed the likelihood ratio test to compare the null model (adjusting for age at 
diagnosis and cohort membership) with the full model (additionally including the genes in the candidate 
pathway) in logistic regression model. 
† The analysis was not performed for men with Gleason 5-6 because of no lethal case. 
‡ No covariate was controlled for in the gene set enrichment analysis (GSEA), which provides an indication of 
whether the candidate pathway is up-regulated (↑) or down-regulated (↓) in the tumor tissue of lethal prostate 
cancer. 
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The differential signaling of the adrenergic pathway was associated with increased cell 
proliferation and higher Gleason score (Table 15), and tended to be related to increased 
angiogenesis (i.e., vessel area and diameter of blood vessels) and perineural invasion. The 
significant associations were noted for the glucocorticoid signaling in terms of cell 
proliferation, angiogenesis (except for the microvessel density), perineural invasion, Gleason 
score, and tumor stage. The differential signaling of the serotoninergic pathway was only 
significant in tumor tissue with perineural invasion.  
Table 15. P-values of pathways analyses in terms of biomarkers and histopathological 
characteristics in the PHS and HPFS Prostate Tumor Tissue Cohort.  
 N Adrenergic pathway 
Glucocorticoid 
pathway 
Serotoninergic 
pathway 
Dopaminergic 
pathway 
Cell proliferation* 314 0.0061 <0.0001 0.49 0.096 
Apoptosis* 255 0.24 0.29 0.50 0.51 
Angiogenesis*      
  Microvessel density 174 0.13 0.21 0.31 0.19 
  Vessel area 174 0.031 0.0001 0.58 0.051 
  Diameter of vessels 174 0.025 0.0001 0.79 0.10 
Perineural invasion 132 0.025 0.0002 0.0097 0.032 
Gleason score† 404 <0.0001 <0.0001 0.54 0.078 
Tumor stage‡ 404 0.070 0.003 0.66 0.52 
PSA at diagnosis§ 341 0.25 0.06 0.42 0.37 
* The biomarkers were classified into four levels according to quartiles. 
† Gleason score was classified into 5-6, 3+4, 4+3, and 8-10. 
‡ Tumor stage was classified into T1/T2, N0/Nx, M0; T3, N0/Nx, M0; and T4, N1, M1. 
§ PSA (prostate-specific antigen) levels at cancer diagnosis were classified into 0 to 3.9 ng/ml, 4 to 9.9 ng/ml, 
and ≥10 ng/ml. 
 
6.4 STRESS-RELATED SIGNALING PATHWAYS AND LETHAL PROSTATE 
CANCER IN SWEDISH MEN WITH LOCALIZED DISEASE (PAPER IV) 
In the Swedish sample, men with lethal cancer were older at cancer diagnosis and more likely 
to have Gleason score≥7 and stage T1b, compared to men with nonlethal cancers (Table 16).  
Table 16. Clinical characteristics of men with localized prostate cancer in Paper IV. 
 Lethal cancer Nonlethal cancer 
Total number 186 325 
Age at diagnosis, years±SD 74.1±6.6 71.5±6.6 
Gleason score, N(%)   
  4-6 39 (21.0) 179 (55.1) 
  7 64 (34.4) 95 (29.2) 
  8-10 62 (33.3) 26 (8.0) 
  Unknown 21 (11.3) 25 (7.7) 
Tumor stage, N(%)*   
  T1a 43 (23.1) 168 (51.7) 
  T1b 143 (76.9) 157 (48.3) 
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Pathway analysis 
We found that the differential signaling of the serotoninergic pathway was significantly 
associated with the risk of lethal prostate cancer (P=0.007; Table 17). Differential expression 
of adrenergic and glucocorticoid pathways was also suggested between lethal and nonlethal 
prostate cancers (P=0.014 and P=0.020, respectively).  However, no association remained 
statistically significant when adjusting for, or stratified by, tumor stage or Gleason score. In 
the sensitivity analysis, we restricted the analyses to the specific genes in each pathway, and 
differential expressions were suggested for the serotoninergic, adrenergic, and glucocorticoid 
pathways. 
The association of differential signaling of the serotoninergic pathway was statistically 
significant for increased cell proliferation and TMPRSS2-ERG fusion, as well as suggested 
for inhibited apoptosis (Table 17). Significant associations with cell proliferation and 
TMPRSS2-ERG fusion were also noted for the adrenergic pathway. Genes in the 
glucocorticoid pathway were differentially expressed in tumors with a Gleason score of 8-10 
or with the TMPRSS2-ERG fusion. 
Table 17. P-values of pathway analyses in terms of lethal prostate cancer as well as 
biomarkers and histopathological characteristics in the Swedish Watchful Waiting 
Cohort.  
 N Adrenergic pathway 
Glucocorticoid 
pathway 
Serotoninergic 
pathway 
Dopaminergic 
pathway 
Number of genes  95 49 48 31 
Lethal cancer      
Primary model* 262 0.014 0.020 0.007 0.092 
Adjusting for stage 262 0.013 0.029 0.008 0.063 
Adjusting for stage and 
Gleason 236 0.093 0.346 0.211 0.161 
Stratified by Gleason      
  Gleason 4-6 89 0.797 0.623 0.528 0.791 
  Gleason 7 95 0.462 0.151 0.795 0.335 
  Gleason 8-10 52 0.585 0.880 0.994 0.673 
Stratified by stage      
  T1a 79 0.119 0.445 0.047 0.958 
  T1b 183 0.112 0.067 0.089 0.059 
The sensitivity analysis† 262 0.017 0.006 0.026 0.203 
Secondary outcomes*      
Cell proliferation 217 0.0001 0.090 <0.0001 0.001 
Apoptosis 250 0.161 0.222 0.016 0.047 
TMPRSS2-ERG fusion  178 0.005 0.012 0.001 0.043 
Gleason 8-10 236 0.182 0.0001 0.152 0.138 
Tumor stage T1b  262 0.224 0.211 0.443 0.846 
Perineural invasion  257 0.107 0.144 0.539 0.231 
PIN 257 0.502 0.164 0.379 0.127 
* In the primary model, we performed the global test based on logistic regression model for the analyses of lethal 
cancer, TMPSS2-ERG fusion, Gleason8-10, tumor stage T1b, perineural invasion, and prostatic intraepithelial 
neoplasia (PIN), whereas the test based on linear regression model was used for the analyses of cell proliferation 
and apoptosis. All primary models were adjusted for age at diagnosis. 
† In the sensitivity analysis, we restricted the genes in the candidate pathways to a set of specific genes, which 
were not shared with other three pathways. The number of genes was 56 for adrenergic, 34 for glucocorticoid, 18 
for serotoninergic, and 8 for dopaminergic pathway. 
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SNP analysis 
Among the 30 candidate SNPs, we only found three that were, or tended to be, associated 
with the risk of lethal prostate cancer (Table 18). Based on the over-dominant model, the 
genetic variation of rs2296972 in HTR2A (in the serotoninergic pathway) carried a decreased 
risk of lethal cancer (OR 0.49, 95% CI 0.31-0.76, P=0.002), whereas the risk of lethal cancer 
tended to be higher among men with homozygous rs33388 in NR3C1 (in the glucocorticoid 
pathway) and rs6277 in DRD2 (in the dopaminergic pathway). No association of genetic 
variants of these SNPs were noted for biomarkers and histopathological characteristics, 
except for the variation of rs6277 that tended to be associated with stage T1b. 
Further analyses showed that the variation in rs2296972 in HTR2A was associated with the 
expression of GNAI1 and GNAI2 in the serotoninergic pathway (P=0.035 and P=0.023, 
respectively), whereas the variation of rs6277 in DRD2 was correlated with the expression of 
FOS and SRC in the dopaminergic pathway (P=0.021 and P=0.032, respectively). The 
genetic variation in rs33388 in NR3C1 was associated with expression of genes SMAD4, 
MAPK14, SLC22A1, POU2F1, MMP13, and NFKB1 in the glucocorticoid pathway 
(P=0.010 for SMAD4 and P-values from 0.0125 to <0.05 for the others). 
Table 18. P-values of SNP analyses in terms of lethal prostate cancer as well as 
biomarkers and histopathological characteristics in the Swedish Watchful Waiting 
Cohort*  
 rs2296972 rs33388 rs6277 
Gene HTR2A NR3C1 DRD2 
Lethal cancer    
  Additive model 0.490 0.761 0.198 
  Recessive model 0.075 0.099 0.014 
  Dominant model 0.043 0.361 0.802 
  Over-dominant model 0.002 0.035 0.022 
    - OR (95% CI) 0.49 (0.31-0.76) 1.59 (1.03-2.44) 1.66 (1.08-2.55) 
Secondary outcomes†    
Cell proliferation 0.817 0.190 0.528 
Apoptosis 0.930 0.413 0.388 
TMPRSS2-ERG fusion  0.211 0.256 0.933 
Gleason 8-10 0.421 0.918 0.403 
Tumor stage T1b  0.986 0.654 0.027 
Perineural invasion  0.477 0.493 0.267 
PIN 0.141 0.920 0.262 
CI, confidence interval; OR, odds ratio; PIN, prostatic intraepithelial neoplasia. 
* We performed the logistic regression model for the analyses of lethal cancer, TMPSS2-ERG fusion, Gleason8-
10, tumor stage T1b, perineural invasion, and PIN, whereas the linear regression model was used for the 
analyses of cell proliferation and apoptosis. No covariate was controlled for in the models. 
† Only three SNPs associated with lethal prostate cancer were further assessed in associations with secondary 
outcomes. Given the over-dominant model fitting the SNP analysis best for lethal prostate cancer, the 
associations with secondary outcomes were therefore all based on the over-dominant model. 
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7 DISCUSSION 
7.1 STUDY DESIGN, BIAS AND CONFOUNDING 
7.1.1 Cohort and nested case-control studies 
Many analytic studies about the impact of psychological stress on cancer incidence were 
carried out using the case-control design,(3) comparing different aspects of psychological 
stress among cancer patients with cancer-free individuals. Commonly, the selection of 
controls was not population-based and the assessment of stress was retrospective. On the 
other hand, a well-designed cohort study holds the unique advantages of minimal selection 
and recall bias. The nested case-control design that we employed for the analyses of cervical 
dysplasia and cancer in Paper I is computationally less demanding and equivalent to the full 
cohort analysis in validity.(171) Cohort studies could be very costly, whereas only a portion 
of the biological samples from the entire cohort are tested, for example the HPV status, if 
using the nested case-control design. This is one of the major reasons that the NCSR and 
Uppsala Studies we used for analysis of HPV infection in Paper I were originally conducted 
using the nested case-control design. Although we adopted the case-control design for this 
analysis, the included control women (i.e. without in situ or invasive cervical cancer) were 
randomly selected from the screening participating population in several Swedish counties. 
Moreover, the loss of a family member was identified from the prospectively collected 
information in national registers, which is less prone to recall bias. Cohort studies can be very 
time-consuming, for instance when studying cervical cancer survival. Given the unique 
personal identification number in Sweden, we were, however, able to follow all individuals in 
the cervical cancer cohort in Paper II through cross-linkage to national public and health 
registers, such as the Causes of Death and Migration Registers. As a result, the register-based 
cohort study, for example Paper II, enables efficient data collection and maintains the large-
scale and virtually complete follow-up.   
The most straightforward approach to study psychological stress is to measure the perceived 
stress level individually. Such information is unfortunately not available in registers. Instead, 
we assessed the loss of a family member as a proxy for psychological stress in Paper I. 
Similarly, we examined psychological stress using the stress-related mental disorders and 
several major stressful life events (including loss of a family member) in Paper II. Although 
these proxies are highly correlated to psychological stress, the magnitude of perceived stress 
levels are also influenced by individuals’ coping strategies and levels of social support.(172) 
That said, the misclassification of exposure exists to some extent in our analyses. For 
instance, it is plausible that divorce is not very stressful for some individuals (Paper II). 
However, such misclassification (i.e., not stressed individuals were classified to the exposed 
group) would theoretically dilute the risk in the exposed group and lead to an underestimated 
relative risk. Indeed, we observed weaker associations of divorce with cancer-specific 
mortality among patients with cervical cancer. To further allay such concern, we also 
performed analyses on types and numbers of stress indicators to shed light on the magnitude 
of stress level that the individuals actually perceived. It is possible that loss of a family 
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member due to unnatural cause of death (i.e. suicide or accident) is in general more stressful 
compared with loss due to natural death (e.g. chronic disease). Reassuringly, in both Papers I 
and II, we noted that the association of loss due to unnatural causes of death was consistently 
stronger in terms of the risks of cervical cancer incidence and mortality. We also showed a 
clear dose-response effect of loss of a family member on the risks of cervical dysplasia and 
cancer: the more losses experienced, the higher the risk of cervical carcinogenesis. 
In both Papers I and II, we obtained the information on cancer incidence and mortality from 
the Cancer and Causes of Death Registers, which were evaluated as complete and valid 
sources in general.(133,135) We also measured the HPV status and viral load using standard 
and validated methods.(138,140,173,174) Minimal information and misclassification biases 
in the ascertainment of outcomes were therefore assured for both studies. However, in Paper 
I, some cervical dysplasia might have been misclassified as normal cytology (i.e. the 
controls), because cervical cytology is well-recognized for its high specificity but moderate 
sensitivity.(7) Such potential misclassification, if any, should be non-differential in terms of 
women’s status of loss of a family member, which would have only attenuated the true 
association of loss with the risk of abnormal cytology. Studies addressing cervical dysplasia 
using validated histological diagnosis are, however, warranted in future. 
One of the most apparent limitations of the register-based cohort studies is perhaps the lack of 
information on potential confounders. For example, socioeconomic status may be associated 
with both loss of a family member and the risk of cervical cancer. However, we carefully 
adjusted the analyses for, and stratified the analyses by, screening adherence, whenever 
possible, in Paper I. It is well-recognized that screening adherence is highly correlated to 
socioeconomic status(175), as well as the risks of cervical dysplasia and cancer. In Paper II, 
we have also thoroughly adjusted for educational level at the time of cancer diagnosis as a 
proxy for socioeconomic status in all analyses. Lifestyle factors are potential confounders for 
the association of stress with the risk of cervical cancer incidence; and, to some extent, are 
correlated to the socioeconomic status and screening adherence as well. However, in Paper I, 
we showed that women with loss of a family member did not significantly differ from women 
without loss in terms of several known lifestyle risk factors for cervical cancer, such as 
smoking, use of oral contraceptives, and sexual behaviors.(40-42) This analysis was 
performed in a small subset of women who were randomly selected from the screening 
participating population in Sweden and were interviewed  (participation rate >90%).(146) 
Moreover, the stronger association observed for the infection of high-risk HPV types, 
compared with low-risk types, refutes the possibility of a complete explanation by lifestyle 
factors for our findings, presuming that the lifestyle factors alone would have introduced 
equally increased risks for both types. Most importantly, lifestyle factors are more likely 
mediators, representing one mechanism linking together bereavement and higher risk of 
cervical cancer, and should therefore not be adjusted for. For instance, it is plausible that loss 
of a family member entails potential change of lifestyle, and subsequently alters the risk of 
cervical cancer. Similarly, in Paper II, the tumor stage and cancer treatment could also serve 
as both confounders and mediators. It is plausible that receiving a cancer diagnosis with 
  45 
advanced stage is more stressful and also more likely to lead to death from the cancer disease 
(i.e., acting as a confounder). It is also possible that individuals with mental disorders 
attended cervical screening less frequently and therefore are more likely to have advanced 
stage at diagnosis, and thereby higher mortality (i.e., acting as a mediator). Although we 
found robust associations either with or without adjustment for these covariates, the true 
estimates of the total effect of psychological stress on cancer-specific mortality might lie 
somewhere in between. Finally, due to the nature of observational studies, we cannot rule out 
the impact of residual confounding (if any) in our findings. 
It is also plausible that the onset of mental disorders shortly before death is secondary to the 
terminal disease of patients that were dying of cervical cancer. But, we observed a significant 
association with cancer-specific mortality excluding the first two years of follow-up after the 
onset of mental disorders, which largely alleviates the concern of reverse causality.   
7.1.2 Extreme case-control studies 
The growth of large-scale cohort studies, such as PHS and HPFS, has produced large 
repositories of clinical data and biological samples. For disease like prostate cancer, many 
have a relatively benign course (i.e. nonlethal disease). Measuring biomarkers in a large 
portion of nonlethal disease is costly and not efficient to identify potential biological 
signatures for prognosis. For optimal use of available information in the data, the extreme 
case-control design has been implemented. In this design, all lethal diseases (defined as 
patients who died of prostate cancer or developed distant metastasis during follow-up in 
Paper III; and patients who died of prostate cancer during follow-up in Paper IV) were 
included as cases and nonlethal diseases were randomly sampled from the sub-cohort, in 
which patients did not die of prostate cancer (and did not develop metastasis) during certain 
follow-up, as controls. Any potential difference in exposure (i.e. gene expression and genetic 
variants) between cases and controls would be expected to be the most evident in these 
“extreme” groups. It has been shown that the extreme case-control design gains in statistical 
power when assessing the quantitative phenotype, compared to the standard cohort 
approach.(176). Regarding the sampling of nonlethal diseases in Paper III, we oversampled 
men with available blood samples, but their clinical characteristics were comparable to all 
men with nonlethal disease in the entire cohort. 
Gene expression in Papers III and IV was measured based on 0.6 mm biopsy cores taken 
from tumor-enriched areas (>90% tumor cells) in the dominant nodules or the highest 
Gleason pattern in FFPE tissue blocks. Adjacent normal tissues were also used for 
genotyping in Paper IV. We used standard and validated methods to measure the gene 
expression and genetic variants in both studies.(158,177,178) It is plausible that the mRNA 
differences we observed in both studies may in part be attributable to the tumor 
microenvironment (such as peripheral neurons or stromal cells). Reassuringly, gene 
expression in adjacent cells are highly correlated to the tumor cells, because of the field effect 
where tumor and adjacent cells tend to be alike in many biological aspects,(179) and is 
unlikely to be the driving force for the noted associations. Compared to the whole-
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gene expression in Paper III, fewer genes were profiled in Paper IV (i.e., 18-37% genes in 
pathways were not tested for expression). However, the global test confined every gene to 
have a small contributory effect on the overall pathway effect, which alleviated concern about 
the bias of selected genes in our findings. Possible technical biases, such as batch effect and 
varying sample quality, have been addressed in data pre-processing. 
Potential confounders, such as age at diagnosis and cohort membership, were adjusted for 
throughout the analyses for gene expression. Tumor stage and Gleason score were primarily 
considered as mediators linking differential gene expression to lethal cancer instead of 
confounders, and were only adjusted for in a secondary model. For instance, we found the 
differential signaling of the glucocorticoid pathway was related to higher Gleason scores in 
both studies, and was significantly associated with lethal cancer even when adjusting for 
tumor stage and Gleason score in Paper III. Such results lend some support to the possible 
contribution of the glucocorticoid pathway to the risk of lethal prostate cancer mediated 
through tumor differentiation. The interaction between different stress-related pathways, 
namely the crosstalk, may potentially drive the differential signaling of individual pathways 
in the tumor tissues of lethal cancer. The individual contribution of the glucocorticoid 
pathways was further strengthened by the remaining associations when we restricted the 
analyses to genes exclusive or specific to the studied pathways in Papers III and IV.  
We corrected for multiple testing by using P<0.0125 as statistical significance for all pathway 
analyses. In the SNP analyses, we still focused on the same four pathways and therefore 
made no further corrections for multiple comparisons, which might have resulted in some 
false positive findings. However, we emphasize the fact that the consistent results(180) for 
both pathway-based gene expression and genetic variants, particularly in serotoninergic 
pathway, largely refutes the possibility of pure explanation by chance finding. 
Finally, we only assessed gene expression at a single time point for each man, and therefore 
we only captured a biological snapshot to examine the potential differences of stress-related 
pathways between lethal and nonlethal cancers. This approach does not allow us to make any 
temporal or functional claims, because it is unknown when the signaling started to alter and 
how they would have further interacted with cancer treatment. Reassuringly, we corroborated 
the findings of the US study with the results of the Swedish study in which the lethal outcome 
largely reflects the natural course of localized disease without any initial treatment. 
7.2 GENERAL DISCUSSION 
7.2.1 Psychological stress and cervical carcinogenesis 
Cervical cancer initiation 
In Paper I, we systematically demonstrated that the loss of a family member, as an extremely 
stressful life event, is consistently associated with increased risk of every known step of 
cervical cancer initiation, including oncogenic infection of HPV, cervical dysplasia, and 
invasive cervical cancer. 
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Psychological stress has been linked to increased risk of infection of several oncogenic 
viruses in cell lines and animals.(5) We, for the first time, showed that psychological stress, 
using loss of a family member as a proxy, was positively associated with HPV infection in 
humans, particularly oncogenic infection for cervical carcinogenesis. The oncogenic infection 
is well-recognized for infection of high-risk HPV types, especially for persistent infection and 
high viral load infection of HPV16.(7,138) We found a stronger association with repeated 
infections, suggesting that psychological stress may compromise host immunosurveillance 
and consequently increase the risk of persistent or recurrent HPV infection.(5) It has been 
shown that psychological stress reduces T-cell proliferation in response to HPV16 in women 
with cervical dysplasia(181), and stress hormones have also been shown to inhibit the 
immune response by negatively regulating antigen presentation of major histocompatibility 
complex class I.(129) In addition, we noted a stronger association for high viral load infection 
of HPV16, lending further support to the potential role of psychological stress in the 
upregulated expression and malignant transformation of HPV oncogenes, possibly through 
the dysregulation of HPA axis.(5,127,128)  
We further showed that the loss of a family member was consistently associated with 
elevated risk of cervical precancerous lesions and invasive malignancy. Our previous works 
have indicated the increased risk of invasive cervical cancer after loss of a parent in 
childhood or after loss of a child in adulthood.(88,93) Here, we extended the knowledge to 
the earlier steps of cervical cancer development, namely cervical dysplasia and in situ 
cervical cancer. Moreover, we extensively assessed a range of loss events (i.e., loss of a child, 
spouse, sibling, or parent), whereas in earlier studies only one specific type of loss was 
examined.(8,88,93,94) Furthermore, we evaluated whether age modified the risk of cervical 
cancer after different types of loss events. Of note, loss of child, sibling, or spouse was 
consistently associated with a greater risk of in situ and invasive cervical cancer throughout 
the life span, whereas the excess risk of these outcomes after loss of a parent was only noted 
in early life. Lastly, although based on a small subgroup of the study participants, our 
findings were less likely to be entirely explained by the differential lifestyle factors between 
women with and without loss of a family member, such as smoking, use of oral 
contraceptives, and sexual behavior. 
Together with the apparent dose-response relationship by number and type of losses, our 
consistent findings throughout all steps of cervical cancer initiation lend strong support to the 
notion that psychological stress contributes to cervical cancer initiation, likely through 
enhanced oncogenic infections of HPV.  
Cervical cancer progression 
In Paper II, we found that 43% of the cervical cancer patients experienced at least one stress-
related mental disorder or stressful life event from one year before cancer diagnosis until end 
of follow-up (average 4.3 years after diagnosis). The cancer-specific survival was 
significantly shortened for the exposed patients, regardless of other prognostic indicators 
including tumor characteristics and cancer treatment. 
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Except for depression, the impact of anxiety, stress reactions and adjustment disorders on the 
risk of cancer-specific mortality have not been extensively studied among patients with 
cancer.(182) The limited evidence on preexisting mental disorders and mortality in any 
cancer has suggested heterogeneous associations across these disorders.(182,183) However, 
we found that among patients with cervical cancer, depression, anxiety, stress reaction, and 
adjustment disorders, either collectively or individually, were consistently associated with a 
60%-116% risk elevation of cancer-specific mortality. The consistent findings in our data, 
compared to the conflicting results in earlier studies, might to some extent be explained by 
the different cancer type studied. It is highly plausible that, due to the known social 
stigma(184) and a drastically reduced quality of life(185) among patients with cervical 
cancer, the mental disorders diagnosed immediately before or after the diagnosis of cervical 
cancer largely reflect patients’ severe stress response toward a potential maladjustment of the 
cancer diagnosis and treatment. That said, the recent onset of stress-related mental disorders 
might help to identify a subgroup of emotionally vulnerable patients. It was reported that 
gynecologic cancer patients with preexisting mental disorders had increased cancer-specific 
mortality in Australia, due to lower rate of surgery and radiotherapy.(182) In our data, even 
though we controlled for primary treatment including surgery and adjuvant therapy, we still 
noted an increased risk of cancer-specific mortality after a recent onset of stress-related 
mental disorder.  
The association of specific stressful life events, such as loss of a family member and 
divorce,(9,10) with cervical cancer survival has been assessed in a few previous studies. 
Here, we showed that four major life events, including loss of a family member, severe 
illness of a family member, divorce, and job loss, either collectively or individually, were 
consistently associated with a 21%-35% increased risk of cancer-specific mortality, although 
some associations were not statistically significant. Our findings on loss of a family member 
and divorce are in general in line with other Nordic studies.(8-10) Another merit of our study 
is that we extended the knowledge base by showing that other life events, i.e., severe illness 
of a family member and unemployment, may have similar impact on cancer-specific survival 
among patients with cervical cancer. 
Experimental studies have convincingly demonstrated that psychological stress might 
modulate tumor growth and progression through the dysregulation of the HPA axis and SNS, 
regarded as the “direct” effect.(4) Additionally, psychological stress may also play a role in 
cancer prognosis through potentially delayed diagnosis or altered treatment plan. The so-
called “indirect” effect has been suggested among individuals with mental disorders and 
unmarried individuals.(182,186) Studies have rarely been able to separate the contributions of 
differential tumor stage and cancer treatment from the overall effect of psychological stress 
on cancer-specific mortality.(182,187) Indeed, tumor characteristics and cancer treatment 
may to some extent contribute to the observed associations, because in Paper II most 
associations attenuated somewhat, although never disappeared, after exhaustive adjustments. 
Regardless, the overall associations remained robust for both mental disorders and life events, 
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independent of aforementioned clinical characteristics and cancer treatment, lending strong 
support to a biological “direct” effect of psychological stress on cervical cancer progression.  
Together with our findings in cervical cancer initiation (Paper I), the findings in Paper II 
highlight a salient role of psychological stress in cervical carcinogenesis, from cancer 
initiation to progression. This consistency may lend further support to the same biological 
theory that also links stress to cervical cancer progression, namely psychological stress 
modulates cervical cancer progression potentially through compromised immunosurveillance. 
Future studies are however needed to confirm or refute such hypothesis. 
7.2.2 Psychological stress and prostate cancer progression 
In Papers III and IV, instead of assessing psychological stress through stressful life events, we 
examined the signaling of four neuroendocrine pathways, with a confirmed link to 
psychological stress, in the tumor tissue of prostate cancer. We found that, in both US and 
Swedish samples, the expression of genes from these stress-related pathways in the tumors of 
men with lethal prostate cancer significantly differed from men with nonlethal cancer. The 
effects of adrenergic and glucocorticoid pathways were more pronounced in the US sample 
where more patients had relatively advanced tumor stage and Gleason score, whereas the 
serotoninergic pathway appeared to play a more important role in the Swedish sample where 
more men had localized disease. The potential underlying mechanisms may include cell 
proliferation, tumor differentiation, perineural invasion, and TMPRSS2-ERG fusion. In the 
Swedish sample, we also found that genetic variation of receptor genes, particularly of HTRs, 
may explain in part the differential signaling of pathways, at least in the tumors of men who 
developed lethal cancer from localized disease.  
Adrenergic pathway 
Our findings suggest that the dysregulation of the adrenergic pathway is associated with 
lethal prostate cancer, although the role is less prominent in the localized disease. This is in 
line with previous experimental studies showing that adrenaline and activation of ADRB2 
contribute to the development and local invasion of prostate cancer.(188,189) The GSEA test 
in the US sample indicated that the signaling of the adrenergic pathway was down-regulated 
in the tumors of lethal cancer at the transcription level. Interestingly, the overexpression of 
adrenergic receptor at the protein level has been suggested in metastatic prostate cancer, 
compared to localized cancer.(190) On transcription level, the expression of adrenergic 
receptors was, however, shown to be lower in metastatic than in localized prostate 
cancer.(191) The paradox between transcription and protein levels of adrenergic signaling 
may simply suggest a possible negative feedback loop due to long exposure to an agonist, 
such as chronic stress.(192) Alternatively, the down-regulated signaling of the adrenergic 
pathway may be engaged with de-differentiation and epithelial-mesenchymal transition so 
that the tumor cells gain more potential to invade and migrate.(112) In addition, we found 
that the differential signaling of the adrenergic pathway was associated with increased cell 
proliferation in both studies, suggesting a potential mechanism underlying the link between 
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adrenergic pathway and lethal prostate cancer. It has also been shown that the enhanced 
signaling of the adrenergic pathway facilitated tumor proliferation in prostate and ovarian 
cancers in animal models.(188,193) However, we did not find any evidence to support the 
association between genetic variation of adrenergic receptor genes and cancer progression in 
localized disease. 
Glucocorticoid pathway 
We found a broadly consistent association of differential signaling of the glucocorticoid 
pathway with risk of lethal prostate cancer in both the US and the Swedish studies, although 
the association was relatively weaker in the Swedish study of men with localized disease. The 
fact that the differential expression of the glucocorticoid pathway was not statistically 
significant in the GSEA test in Paper III was likely because two driving genes – PTGES3 and 
SMAD4 – in the pathway had opposite associations with lethal cancer, and GSEA is more 
powerful when testing pathways with genes demonstrating effects in the same direction. It is 
plausible that the glucocorticoid pathway may assist the transition of prostate cancer cells 
from androgen- to glucocorticoid-dependence growth. While androgens supports tumor cell 
growth throughout the early stage of prostate cancer, glucocorticoids could directly 
orchestrate the growth of prostate cancer through mutated androgen receptors and acquire 
androgen-independent growth in a later stage.(194) Of note, in Paper IV, the downstream 
cascade of the glucocorticoid pathway subsequent to SMAD4 is possibly bypassed by the 
TGFβ/SMAD4 signaling axis, which is well-recognized for its role in prostate cancer 
development.(195,196) That said, the downstream genes included in the glucocorticoid 
pathway might be less relevant to cancer progression in localized disease. Indeed, in Paper 
IV, we observed stronger associations in sensitivity analysis where those genes were 
excluded. We have also noted consistent relationships between differential glucocorticoid 
signaling and increased cell proliferation in both studies. Although glucocorticoids have the 
potential to suppress the androgen synthesis and subsequently inhibit tumor growth in some 
prostate cancer,(197) the differential signaling of glucocorticoid pathway may transform 
tumor cells to androgen-independent prostate cancer and further accelerate cell 
proliferation.(198) In addition, the genetic variant of NR3C1 (rs33388) may partly explain 
the increased lethal cancer risk through the correlation with expression of a number of genes 
(including SMAD4) in the glucocorticoid pathway.  
Serotoninergic pathway 
We observed consistent association of differential signaling of the serotoninergic pathway 
with the risk of lethal prostate cancer in both the US and the Swedish studies. Interestingly, 
the role of serotoninergic signaling, compared to other stress-related pathways, is more 
prominent among men with localized disease. Genes in the serotoninergic pathway have 
previously been linked to prostate cancer differentiation: over-expression of HTR1, HTR2, 
and HTR4 in high-grade cells and over-expression of HTR2 in low-grade cells of prostate 
cancer.(199,200) It has been suggested that the downstream regulatory pathway through 
MAP kinase and PI3K/Akt signaling plays a critical part in prostate cancer progression.(201) 
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However, the pharmacologic effects of serotonin on cell lines remain inconclusive. 
(199,200,202,203) The serotoninergic signaling seemed to exert an influence on cell 
proliferation and apoptosis, though such associations were only noted in the Swedish sample. 
It is in line with in vitro studies showing that activated serotonergic receptors facilitate cell 
proliferation in prostate cancer, and that blocking the receptors induce apoptosis.(110)  
Moreover, we showed a protective effect of the genetic variant of HTR2A (rs2296972) on the 
risk of lethal prostate cancer in localized disease. The interpretation of the results from the 
over-dominance model is not clear, but it is not inconceivable that the heterozygote carries a 
more influential effect on the phenotype than the homozygote (i.e. heterosis).(204) 
Heterozygote advantage in various health outcomes has been documented for multiple 
neuroendocrine genes, including HTR2A.(204) It is plausible that a third factor –  
psychological stress in our case – may also interact with the molecular expression 
independent of the expected additive effect of genetic polymorphism.(204) This SNP was 
further correlated to the expression of G protein subunits coupling with serotoninergic 
receptors in the serotoninergic pathway (i.e., GNAI1/2). Together with the findings at 
translational level, we propose that the genetic predisposition of HTR2A may contribute to 
the risk of lethal prostate cancer through serotoninergic signaling in localized disease. As a 
first possible piece of evidence, we however cannot rule out alternative contributory effects 
of, for example, somatic mutations in tumor cells or post-translational modifications, in the 
differential signaling of serotoninergic pathway. 
Of note, in the US sample, none of the above pathways was differentially expressed in 
adjacent normal tissue obtained from the same lethal cases, compared to the normal tissue 
from nonlethal cases. It is plausible that tumor cells and normal cells respond to stress 
differently. Our data from both studies did not support a prominent role of dopaminergic 
signaling in prostate cancer progression. In the Swedish sample, the differential signaling of 
the four stress-related pathways was consistently associated with the presence of TMPRSS2-
ERG fusion, which lends further support to the suggested role of TMPRSS2-ERG in 
neuroendocrine transformation of prostate tumor cells.(205) Although not noted in the 
Swedish sample, the consistent associations of differential signaling of all pathways with the 
presence of perineural invasion were found in the US sample. This finding requires further 
investigation, though it may in part reflect the high correlation with lethal outcome.(72,206) 
In Papers III and IV, we demonstrated the molecular differences in the stress-related 
pathways, namely the adrenergic, glucocorticoid, and serotoninergic pathways, in tumors of 
lethal prostate cancer, compared to nonlethal cancer. Such differential signaling may also be 
involved in tumors with different histopathological features, including cell proliferation, 
tumor differentiation, perineural invasion, and TMPRSS2-ERG fusion. Furthermore, genetic 
predisposition may contribute to prostate cancer progression in localized disease, through 
differential signaling in particular of the serotoninergic pathway. Altogether, our findings 
provide considerable support to the neuroendocrine link between psychological stress and 
prostate cancer progression.   
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8 CONCLUSIONS 
• Loss of a family member is consistently associated with all known steps of cervical 
cancer initiation, from cervical dysplasia to invasive cancer, potentially through 
enhanced oncogenic infections of HPV. Our findings shed light on the possible 
modulating effect of psycholocial stress on malignant transformation after a primary 
HPV infection. 
• Stress-related mental disorders and stressful life events are associated with 
compromised cancer-specific survival, independent of tumor characteristics and 
cancer treatment. Our results provide further support to the contribution of 
psycholocial stress on cervical cancer progression, in addition to initiation. 
• Signaling of stress-related pathways, particularly adrnergic and glucocorticoid 
pathways, may be dysregulated in tumors of US men with lethal prostate cancer, 
compared to nonlethal cancer. These results indicate potential roles of neuroendocrine 
pathways in prostate cancer progression. 
• Differential expression of stress-related pathways, particuarly the serotoninergic 
pathway, may be involved in cancer development from localized prostate cancer to 
lethal cancer among Swedish men. Such difference may to some extent be explained 
by genetic predisposition. 
  
  53 
9 FUTURE PERSPECTIVES 
A growing body of evidence from both experimental and epidemiological studies supports a 
role of psychological stress in carcinogenesis. However, challenges remain in order to yield 
more consistent findings in epidemiological studies. 
First, consistent and feasible measurements of psychological stress should be established for 
epidemiological studies. The diverse definition of stress in the current literature, ranging from 
poor quality of life to emotional liability to depression, may largely explain the highly 
heterogeneous results.(3) More consistent findings are, however, noted when “extreme” 
stress (e.g. extremely stressful life event such as loss of a family member) is examined. 
Although a range of valid rating scales are available for stress measurement, developing a 
register-based stressor matrix to individually assess stress level would greatly benefit future 
epidemiological studies, especially in countries with available public and health registers. The 
methods used in Paper II stand as a good exercise to better capture the emotional burden from 
different stress sources among cancer patients. 
Secondly, multiple biological mechanisms exist underlying the link between stress and 
cancer, and therefore the effects of stress may vary across cancer types. This may also, in 
part, explain the conflicting associations observed in previous studies that were possibly not 
assessing the most relevant cancer types.(3) Future research may focus on certain cancer 
types according to specific biological mechanisms. For example, as shown in Paper I, 
cervical cancer may be of particular interest to pursue, given the specific mechanism of 
stress-induced immunosuppression and oncogenic infection. Studies in other infection-related 
cancers, especially virus-related, are warranted in future. In addition, the behavior-related 
cancers, such as lung and liver cancers, may also be highlighted by possible behavioral 
pathways, because stress has been show to increase the risk of smoking and alcohol 
consumption.(207,208)       
Thirdly, cancer-specific survival should be examined to estimate the impact of stress on 
cancer progression. Receiving a cancer diagnosis, as well as living with cancer, is by nature 
stressful, and have been associated with elevated risks of suicide and cardiovascular 
deaths.(209) It is therefore plausible that the estimates based on overall cancer survival are to 
some extent driven by these conditions with a clear and immediate link to stress. Previously, 
none of the three studies in cervical cancer (Table 1), and only one study in prostate cancer 
(Table 2), specifically assessed the cancer-specific survival. As we did in Papers II-IV, using 
the cancer-specific survival as the primary outcome may help capture the “net” effect of 
stress on cancer progression in future studies. 
Another challenge is having large enough sample size. It is plausible that the effect of stress 
on the risks of cancer initiation and progression is modest. To detect a precise and statistically 
significant association, very large sample sizes would then be required. This possibly 
explains the varying findings in many studies with smaller size. Merging registers in Nordic 
countries could form a unique and powerful resource and provide potential clues on this 
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puzzle by comprehensively exploring individual stressor, cancer type, and cancer-specific 
mortality. 
Last but not least, a great deal of research is required to translate the findings on stress and 
carcinogenesis to cancer prevention and care. Although the prevalence of psychological 
distress is estimated to be high in the general population,(210) no psychological intervention 
studies so far aims to prevent cancer, likely due to the unconvincing link between stress and 
cancer initiation. On the other hand, many trials have shown that psychological intervention 
may reduce stress and improve mood among cancer patients, although very few trials have 
examined whether psychological intervention could benefit cancer survival.(4) Although the 
current findings are inconclusive,(211-216) a “second wave” of trials have been called for to 
target the vulnerable cancer patients(4) and to intervene in early-stage cancers in which the 
metastatic capacity remains physiologically modifiable.(11) Indeed, we have observed 
different weights of stress-related pathways in the progression of early-stage prostate cancer 
(Paper IV), compared to more advanced cancer (Paper III). In addition to psychological 
intervention, novel means of chemical intervention, for instance targeting the adrenergic 
pathway, may also open up new strategies for cancer treatment. Several observational studies 
have revealed that use of beta-blocker – a β-adrenergic antagonist – before cancer diagnosis 
is associated with prolonged survival in prostate, breast, lung, pancreatic cancers and 
malignant melanoma.(115,217-220) Randomized controlled trials are, however, needed in 
future to help draw a causal conclusion.  
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